<table>
<thead>
<tr>
<th>Title</th>
<th>Review on counter measures to coronavirus disease 2019 (COVID-19) pandemic, May 2020</th>
</tr>
</thead>
<tbody>
<tr>
<td>Author(s)</td>
<td>Kidaka, Taishi; Lokupathirage, Sithmini M.W.; Muthusinghe, Bungiriye Devinda Shameera; Pongombo, Boniface Lombe; Wastika, Christida Estu; Wei, Zhouxing; Yoshioka, Shizuka; Ishizuka, Mayumi; Sakoda, Yoshihiro; Kariwa, Hiroaki; Isoda, Norikazu</td>
</tr>
<tr>
<td>Citation</td>
<td>Japanese Journal of Veterinary Research, 68(3), 133-150</td>
</tr>
<tr>
<td>Issue Date</td>
<td>2020-08</td>
</tr>
<tr>
<td>DOI</td>
<td>10.14943/jjvr.68.3.133</td>
</tr>
<tr>
<td>Doc URL</td>
<td><a href="http://hdl.handle.net/2115/79323">http://hdl.handle.net/2115/79323</a></td>
</tr>
<tr>
<td>Type</td>
<td>bulletin (article)</td>
</tr>
<tr>
<td>Additional Information</td>
<td>There are other files related to this item in HUSCAP. Check the above URL.</td>
</tr>
<tr>
<td>File Information</td>
<td>JJVR68-3_133-150_TaishiKidaka.pdf</td>
</tr>
</tbody>
</table>
**Abstract**

An outbreak of novel coronavirus infection occurred in China at the end of 2019, which was designated as coronavirus disease 2019 (COVID-19), and spread to regions across Asia and ultimately all over the world. As of 21 May 2020, a total of more than 5 million cases with more than 350 thousand deaths were reported worldwide. Evaluation of the pathogenicity of the disease and determining the efficacy of control measures are essential for rapid containment of the disease. However, the world is facing difficulties in controlling COVID-19 at both of the national and global levels due to variations in pathogenicity of infection by severe acute respiratory syndrome coronavirus 2, the causal agent of COVID-19, and to diverse measures applied in each country based on their control capacities and policies. In the present review, we summarize the basic information and findings related to the COVID-19 pandemic, including pathogen agent, epidemiology, disease transmission, and clinical manifestations. Diagnosis, treatment, and preventive measures applied or under development all over the world are also reviewed to provide the opportunity to establish a more effective scenario for disease containment. Humanity has progressed by developing countless great technologies and immense scientific theories, however it may be a fact that we cannot conquer all risks to humanity. New findings and challenges for the unprecedented pandemic at the global level, such as COVID-19, should also contribute to preparedness for unknown diseases in future, similar to the lessons learnt from severe acute respiratory syndrome and the pandemic A(H1N1)pdm09 influenza.

**Key Words**: COVID-19

**Introduction**

Since the dawn of history, humanity has confronted infectious diseases. Human history is, so to speak, the history of infectious diseases. Symptoms of tuberculosis have been confirmed in...
Egyptian mummies, and the disease was described in early Egyptian texts. Among the greatest plague pandemics ever experienced is the Black Death, which occurred in 1347-1351 and killed 25 million people in Europe. The “Spanish flu” pandemic of 1918-1919 killed approximately 50 million people with mortality of more than 2.5%. Medical science has progressed to conquer infectious diseases by discovering effective treatment methods such as antibiotics and by developing the scientific field of public health. On the other hand, since the 1980s, we have been exposed to a variety of health risks owing to industrialization and increased population; thereby, many infectious diseases spread worldwide quickly. These emerging diseases have become one of the major concerns in public health.

In the 21st century, we have experienced several pandemics. Severe acute respiratory syndrome (SARS) emerged in 2002-2003, causing a total of 8,096 cases with 774 deaths in 29 countries and regions. Pandemic A(H1N1)pdm09 influenza spread from April 2009, and the WHO declared a pandemic from June 2009 to August 2010. Middle East respiratory syndrome (MERS), which was firstly identified in 2012 mainly caused respiratory symptoms with approximately 35 deaths and has been reported in 27 countries as of the end of 2019. The largest outbreak of Ebola virus disease, which is an acute and severe disease with high mortality, since its discovery occurred in 2014-2016 caused approximately 11 thousand deaths out of 28 thousand cases in West Africa. All of these diseases spreading at regional or global levels threatened lives and led to updates of control measures.

In 2020, most countries have come to consider a newly emerging disease, coronavirus disease 2019 (COVID-19), which spread worldwide in the three months since its emergence in January 2020. This article highlights characteristics of COVID-19, including pathogens, epidemiology, and disease symptoms to identify effective control measures including diagnosis, treatments, and prevention methods.

**Pathogen**

The causal virus of COVID-19 was identified as a group of SARS-like coronaviruses and was named 2019 novel coronavirus (2019-nCoV) before the International Committee on Taxonomy of Viruses (ICTV) designated the official name of the virus, on 11 February 2020, as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) based on the similarity of genomic structure with SARS-CoV. At the same time, the WHO announced the official name of the disease as COVID-19.

Due to the crown-like spike on the surface of the virus, a new type of virus was first found in organ cultures in 1965 and named as coronavirus. This virus belongs to the Coronaviridae family in the Nidovirales order. Coronaviruses are single-strand positive RNA viruses, consisting of nucleocapsid protein, envelope protein (E), spike protein (S), membrane glycoprotein (M) and lipid bilayer.

SARS-CoV and MERS-CoV, which cause SARS and MERS, respectively, are also coronavirus targeting the respiratory system in humans. The subgroups of coronavirus families are alpha, beta, gamma and delta; and all three previously mentioned human coronaviruses belong to the betacoronaviruses. When compared with other coronaviruses, SARS-CoV-2 shares 79% sequence identity with SARS-CoV.

The S protein of SARS-CoV-2 binds to the cellular receptor angiotensin converting enzyme II (ACE2) for cell entry, and conformation changing in the S protein through an endosomal pathway mediates fusion between the virus envelope and cell membrane. The open reading frame (ORF) 1a and ORF 1b are made by genome RNA and translated into viral replicase protein pp1a and pp1ab, and then cleaved into 16 nonstructural proteins by viral proteinases. Some of these nonstructural proteins form a replication/transcription complex (RNA-dependent RNA polymerase, RdRp), which use the positive strand genomic RNA as a template. The positive strand genomic RNA produced through the replication process becomes the genome of the new...
virus particle. Subgenomic RNAs produced through the transcription are translated into corresponding structural proteins for forming a viral particle. Since the translated viral proteins and transcribed viral RNA in the cell are subsequently assembled into virions in endoplasmic reticulum and Golgi, and then virions are released out of the cell by exocytosis\textsuperscript{27, 72}.

There are indications that COVID-19 patients show heightened levels of leukocytes and plasma pro-inflammatory cytokines\textsuperscript{44}, while the main pathogenesis of COVID-19 is severe pneumonia with incidence of ground-glass opacities\textsuperscript{38}. Significantly high blood levels of cytokines and chemokines have been noted in patients of COVID-19, including \textit{IL1-\textbeta}, \textit{IL1RA}, \textit{IL7}, \textit{IL8}, \textit{IL9}, \textit{IL10}, basic \textit{FGF2}, \textit{GCSF}, \textit{GMCSF}, IFN\textgamma, IP\textbeta0, MCP1, MIP\textalpha1a, MIP\textbeta, PDGFB, TNF\textalpha, and VEGFA\textsuperscript{38}. Some severe cases that were admitted to the intensive care unit showed high levels of pro-inflammatory cytokines and chemokines including \textit{IL2}, \textit{IL7}, \textit{IL10}, GCSF, IP\textbeta0, MCP1, MIP\textalpha1a, and TNF\textalpha that were suspected to enhance disease severity\textsuperscript{38}.

\textbf{Epidemiology, Transmission, and Situation}

\textbf{Early case of COVID-19}

The WHO received the first official report from China on 31 December 2019 about an outbreak of pneumonia of unknown etiology in Wuhan City, Hubei Province of China\textsuperscript{86}. Further investigation revealed that the first patient showed clinical symptoms on 1 December 2019 without any links to the later cases. The first fatal case was connected to a market in Wuhan and the individual’s wife also showed similar symptoms, though she did not have any history of being exposed at the market\textsuperscript{38}.

\textbf{Human-to-human transmission}

In late January, the WHO announced that SARS-CoV-2 could be transmitted from human to human by droplets, contact, and fomites, similar to the previous outbreaks of MERS and SARS\textsuperscript{86}. Cases related to the Wuhan market decreased in time and family-related clusters were confirmed, supporting the case for human-to-human transmission by close contact, some of which caused asymptomatic infection\textsuperscript{10}. The first case outside China was reported on 13 January 2020 in Thailand followed by Japan (16 January 2020), South Korea and United States (20 January 2020)\textsuperscript{37, 68, 70, 71}.

A German case likely transmitted by a woman from China who was diagnosed as positive to SARS-CoV-2 after travel back from Germany led to suspicions that the virus transmission could occur during incubation period and asymptomatic infection\textsuperscript{62}. A similar finding was reported in China from a family cluster\textsuperscript{6}. Moreover, Zou et al, proposed the possibility of disease transmission from asymptomatic or mildly symptomatic cases based on viral load analysis in nasal and throat swabs\textsuperscript{107}. In April, the WHO reported three mechanisms of human-to-human transmission: symptomatic, pre-symptomatic, and asymptomatic transmissions. Symptomatic transmission refers to the transmission from a person manifesting the typical clinical symptoms to others. During the incubation period of COVID-19 estimated 5-14 days, in which the infected host has not shown apparent symptoms, an infected person could be contagious and transmit the virus, a case of pre-symptomatic transmission. The third type was identified by a COVID-19 case transmitted from a laboratory-confirmed asymptomatic carrier\textsuperscript{87}.

\textbf{SARS-CoV-2 infection in animals}

The first animal infection was reported in two dogs in Hong Kong, whose owner had been diagnosed as positive for COVID-19\textsuperscript{66}. It was reported that several big cats in a zoo in the United States were infected with SARS-CoV-2 via transmission from an asymptomatic zookeeper.
In total, four tigers and three lions showed clinical signs such as dry cough, wheezing, and inappetence. SARS-CoV-2 was isolated from the samples taken from the first affected tiger, and other animals were assumed to be infected with the same virus.

Under laboratory conditions, it was confirmed that cats and ferrets were highly susceptible to SARS-CoV-2, while dogs only showed low susceptibility with poor viral replication. In contrast, domestic animals such as pigs, chickens, and ducks were not susceptible to the virus. Similar to humans, cynomolgus macaques were also susceptible to the infection but did not show severe clinical signs. Another study in cats demonstrated effective transmission of the virus from an infected to healthy cat in the same cage.

During the COVID-19 pandemic, there is a possibility of the occurrence of SARS-CoV-2 transmission from human to animal as described above. Thus, all infected animals have been reported to cohabit with infected humans. Even though the animals were positive in the viral detection test, further investigation in the field are required to assess whether the infected animals can play a key role in the spread of COVID-19 by transmitting the virus back to humans.

Potential origin of the virus in animals

Since an animal market in Wuhan was related to most of the early cases of COVID-19, the virus was suspected being transmitted from an animal host before causing human-to-human infection. The first comparative genomic analysis reported that SARS-CoV-2 was related to a bat coronavirus which is yet unknown. It also suspected that the virus emerged as the result of recombination events and that a snake is an intermediate host, a finding which was ruled out after further analysis.

Metagenomic analysis on bronchoalveolar lavage fluid from a patient in Wuhan revealed that SARS-CoV-2 had 89.1% nucleotide identity with bat-coronavirus SL-CoVZC45 previously isolated in China. Another meta-metagenomic investigation found that SARS-CoV-2 sequence was highly similar to a virus sequence in pangolin lung and to a bat coronavirus (RaTG13). Furthermore, a genome analysis reported that the SARS-CoV-2 uses ACE2, which is the same entry point as SARS-CoV. A study on SARS-CoV-2 entry points described that the virus was using ACE2 and was supported by the cellular transmembrane protease serine 2.

The intermediate host from bat to human has been investigated in detail by genomic analysis and virus characterization and isolation. Phylogenetic analysis based on full-genome sequences showed that the pangolin coronavirus had 91.0% identity to SARS-CoV-2 and 90.6% identity to RaTG13. The receptor binding protein on the S1 protein which is one of the subunits of the S protein and could interact with ACE2 receptor, of SARS-CoV-2 is similar to a pangolin coronavirus. However, neither pangolin coronavirus nor RaTG13 has polybasic furin cleavage site at the S1-S2 junction but SARS-CoV-2 does. This mutation allows the S protein of SARS-CoV-2 to be cleaved by furin and other proteases and is a determinant of the viral infectivity and host range.

Worldwide spread

Due to the rapid increase of COVID-19 cases outside China, the WHO declared the pandemic of COVID-19 on 11 March 2020 which brought global awareness to this outbreak. Following the lockdown of Hubei Province in China, several countries tightening their border control resulted in a decrease in the infection. Hong Kong, Taiwan, and Singapore closed their border in March. Although China authority has banned domestic and international flights from Wuhan since 23 January.

The global spread of COVID-19 was initially due to exported cases from China followed by local transmission within the countries. According to the WHO situation reports, COVID-19 was mainly reported as being imported through over-23-day-international travels outside the West Pacific region (Fig. 1). Through genomic epidemiology, Fauver et al. describe that the transmission shifts in the...
United States has been observed since March. Moreover, inter-state air travels were predicted to be the main factor for the domestic spreading in the US, especially in Connecticut 26, 33, 54).

As of 21 May 2020, COVID-19 cases have reached 4.9 million cases including 324,766 deaths with 1,717,407 patients having recovered worldwide 40). The epi-center of COVID-19 has moved from East-Asia to Europe and the US with a combined 1,532,974 cases followed by Russia (308,705 cases) and Brazil (275,087 cases). In Japan, a total of 16,367 COVID-19 cases has been reported, of which 768 have died and 11,564 recovered.

Fig. 1
Dynamics of COVID-19 transmission in member states. Proportions of member states with imported COVID-19 cases confirmed in the region were calculated by the World Health Organization situation reports from No. 39, (on 28 February 2020) to No. 79 (on 8 April 2020). WPR: Western Pacific Region, SEAR: South-East Asia Region, EMR: Eastern Mediterranean Region, EUR: European Region PAHO; Regions of the Americas, AFR; African Region.

Signs and Symptoms

General symptoms
A wide spectrum of clinical signs and severity have been reported in cases of COVID-19, ranging from asymptomatic to critical, and, ultimately, death. The most common complication of this disease is acute hypoxaemic respiratory insufficiency and ventilation therapies 56). At the time of onset, fever, cough, difficulty in breathing, muscle pain, and fatigue were observed as common signs 43). Most of the signs were observed on the respiratory system, however, digestive symptoms were also observed with or without respiratory symptoms 56). Among digestive symptoms, diarrhea was the most commonly confirmed in both children and adults, with signs being observed a later rather than early stages of disease onset 74).

Olfactory and gustatory dysfunction was also reported, most of which were rapid onsets, although numbers of patients with this symptom varied depending on region 30). The mechanism of these symptoms has not yet been clarified but SARS-CoV-2 can grow in olfactory cells at the early phase of infection, possibly causing smell dysfunction in the patient 7).

Elderly and younger patients
All ages are susceptible to SARS-CoV-2, however, the young people less than 20 years of age, the elderly, and patients with chronic disease, heart disease, or immunocompromised
individuals are considered to be generally at higher risk of adverse outcomes. A strong immune response, such as a cytokine storm, that results in worsening the outcome has been recently reported as well. Though the mechanism of a cytokine storm triggered by SARS-CoV-2 infection has not yet been well understood, administration of corticosteroid appears to reduce excessive inflammatory response, although the timing of administration remains challenging.

Diagnosis

Molecular methods
It has been shown that COVID-19 patients harbor high viral loads in their upper and lower respiratory tract at 5-6 days after manifesting clinical symptoms. Nasopharyngeal and oropharyngeal swabs are commonly collected as upper respiratory samples for screening and early diagnosis of COVID-19. For COVID-19 patients with symptoms of severe pneumonia, sputum or bronchoalveolar lavage are collected as lower respiratory tract specimens to obtain samples with a high viral load. Several studies have shown that SARS-CoV-2 RNA can also be detected in blood and stool specimens, suggesting the safer applicability of rectal swabs for detecting SARS-CoV-2 from severe COVID-19 patients. Specimen processing should be carried out in a biosafety level (BSL) 2 cabinet or ideally in a BSL3 environment.

Most of the molecular diagnostics currently applied to COVID-19 involve real-time RT-PCR, while other molecular methods such as loop-mediated isothermal amplification and multiplex isothermal amplification followed by microarray detection are under development or on trial all over the world. Targets of these tests are viral genes encoding structural proteins of SARS-CoV-2, such as the S, E, M, helicase, and nucleocapsid (N) proteins, RdRp, hemagglutininesterase, and open reading frames ORF 1a and ORF 1b. In the United States, the Center for Disease Control (CDC) recommends two protein targets in the nucleocapsid (N1 and N2) while the WHO recommends E gene assay followed by a confirmatory assay using the RdRp gene as a first line screening test.

Serology
Out of the four structural proteins of SARS-CoV, N protein shows high immunodominance, suggesting its applicability as an antigen of serological diagnosis for COVID-19. A rapid lateral flow assay and other serological tests have been developed and for detection of IgM and IgG antibodies against SARS-CoV-2. As it takes several days for the production of antibodies, these tests are less likely to be useful for early diagnosis of infection.

Radiological diagnosis
Single or multiple ground-glass opacities, especially on the peripheral and lower lobes in the lung in the early phase, and bilateral multiple lobular and subsegmental areas of consolidation were typical findings of chest X-ray or CT image among serious cases.

Treatments

Antivirals
Though many of the specific treatment or medicines are under development, soon after the emergence of COVID-19, several drugs, already developed or approved for therapeutic purpose in other diseases, were applied to COVID-19. Several antiviral agents have shown their efficacies to treat COVID-19 in vitro and in animal models.

Inhibiting the RdRp

Remdesivir
Remdesivir, originally developed as a treatment of Ebola virus infection, was successfully used in several COVID-19 patients in China. As the structure resembles adenosine, remdesivir acts via adding into the synthesizing viral RNA
chain followed by its premature termination. It is currently undergoing multiple trials in different countries, including two randomized phase III trials in China that had been scheduled to be completed in April/May 2020.

**Favipiravir**

Favipiravir, developed by Toyama Chemical, Japan, which is an approved treatment for influenza has a structure resembling the endogenous guanine which works as a competitive inhibitor of the RdRp. This was approved as the first anti-COVID-19 drug in China by the National Medical Products Administration of China, due to the results of a clinical trial demonstrating its efficacy with few side effects.

**Inhibiting the Viral Protease**

**Ivermectin**

This FDA-approved anti-parasitic agent has also been revealed to stimulate antiviral activities toward both human immunodeficiency virus and dengue virus. At 48 hours of infection with SARS-CoV-2, ivermectin reduces viral RNA up to 5,000-fold.

**Blocking Virus–Cell Membrane Fusion**

**Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2)**

It was reported that rhACE2 which blocks the S protein from interacting with cellular ACE2 could inhibit SARS-CoV-2 replication in vitro by a factor of 1,000-5,000. APN01 (rhACE2), originally developed by Apeiron Biologics, has already undergone phase II trial for acute respiratory distress syndrome.

**Hydroxychloroquine**

The effect of this antimalarial agent against SARS CoV-2 has been demonstrated in China and France to varying degrees. Considering this evidence, the US FDA issued the European Unit of Account for the use of hydroxychloroquine to treat COVID-19 in the USA. However, the latest study done using a combination of hydroxychloroquine and azithromycin for the treatment of severe COVID-19 patients found no evidence of clinical benefit.

In addition to the above mentioned antiviral drugs, monoclonal antibodies against interleukins and SARS-CoV-2-specific neutralizing antibodies identified from recovered patients of COVID-19 are being tested for their efficacies. As of 20 May, the National Institute of Health, clinical trials database records 2,276 trials related to COVID-19 and SARS-CoV-2 in total, while the WHO International Clinical Trials Registry Platform lists 2,738 clinical trial records as of 19 May 2020.

**Vaccines**

As of 18 May 2020, 169 total vaccine candidates are on the run in pre-clinical, phase I and phase II trials according to the tracker developed by the Vaccine Centre at the London School of Hygiene & Tropical Medicine. They have categorized these candidates into 8 vaccine types: RNA (n=21), DNA (n=12), non-replicating viral vector (n=16), replicating viral vector (n=15), Inactivated (n=6), live-attenuated (n=3), protein subunit (n=51) and other/unknown (n=45).

**mRNA-1273**

US-based company ModernaTX, Inc made a synthetic messenger RNA (mRNA) strand namely mRNA-1273, encapsulated in lipid nanoparticle envelope that encodes the prefusion-stabilized viral spike protein that is expected to elicit a specific antiviral response. Recruitment of participants for the phase I clinical trial is ongoing in the United States and is estimated to be completed by September 2020.

**INO-4800**

This is a candidate DNA vaccine created by Inovio Pharmaceuticals that can elicit an immune response after being translated into its protein inside host cells. Phase I Open-label Study to Evaluate the Safety, Tolerability and Immunogenicity has started and currently recruiting the healthy study participants. It is expected to be completed in April 2021.
ChAdOx1 nCoV-19
A phase I/II single-blinded, randomized, multi-center study to determine efficacy, safety and immunogenicity of the vaccine candidate ChAdOx1 nCoV-19 created by University of Oxford, UK is currently recruiting study participants and is expected to be completed by May 2021. This vaccine is composed of a non-replicating adenovirus vector carrying the S protein sequence of SARS-CoV-2.

Prevention at the individual level
To date, there is no effective vaccination available for COVID-19 and there is a high risk of acquiring the infection through respiratory droplets and contact. Therefore, the best way to protect oneself is to follow the conventional prevention methods at the individual and community level.

Hand hygiene practices
SARS-CoV-2, like other viruses, has a lipid envelope which hand washing with soap can break apart, thereby destroying the infectivity of the virus. Hence, handwashing with soap and water is more important than any other prevention method thus far established. Furthermore, according to the CDC guidelines, an effective handwashing technique includes 5 steps: wet, lather, scrub, rinse, and dry, all of which should last at least 20 minutes. Due to the unavailability of clean water and soap for those who are travelers, the use of 75% alcohol, hand sanitizer gel, or disinfected wipes are suggested as an instant hand hygiene alternative. A recent study showed that hand wiping using a wet towel soaked in water containing 1.00% soap powder, 0.05% active chlorine, or 0.25% active chlorine from sodium hypochlorite removed 98.4%, 96.6%, and 99.9% of the virus from hands, respectively.

Proper use of face masks
The size of SARS-CoV-2 is estimated to be about 125 nm in diameter. The smallest of them are estimated to be 60 nm and the largest are 140 nm. There are several types of masks used by the general public and healthcare workers, each of which has different filter capacities. Surgical mask is conventionally used in hospitals or publics to prevent dissemination of pathogen spread in exhalation and causing a potential infection by it, whereas N95 respirator is specifically used for protecting individuals from being exposed to any kinds of contamination including infectious agents. According to the guidelines issued by the WHO for the usage of face masks, face masks can be used as a physical barrier for individuals showing respiratory symptoms and health-care workers. Whether healthy members of the public should use face masks is still under discussion. The WHO on 6 April 2020 released advice to decision makers on the use of masks for healthy people in community settings. In addition, there are potential advantages to using masks by healthy individuals such as reducing the risk of exposure during the pre-symptomatic period from infected peoples as well as reducing the stigmatization of individuals wearing masks for source control. Furthermore, it is important to pay attention to appropriate use and disposal of face masks to avoid any increase in transmission.

Disinfection of surfaces
SARS-CoV-2 spreads mostly through contaminated surfaces and respiratory droplets. Therefore, it is not enough to protect oneself only from respiratory droplets using masks. Recent studies have shown that SARS-CoV-2 can persist for hours to days depending on the material of the surfaces. Hence, the CDC recommends cleaning and disinfecting the surfaces of residential and public spaces regularly using appropriate disinfectant. It has been proven that disinfectants with 62-71% ethanol or 0.1% sodium hypochlorite are effective for the disinfection of surfaces contaminated with SARS-CoV-2. Cleaning of the surfaces should be done followed by the disinfection of the surfaces.
Also, it is important to pay attention to shared instruments and electronic devices such as public telephones and shared computers. Disinfection should be applied prior to usage or hand hygiene methods should be applied after the usage of shared devices.

Implementation of social distancing

Social distancing is a widely accepted method worldwide to fight COVID-19 infection. Social distancing can also be described as “physical distancing” which can be applied to individual and community levels. According to the WHO guidelines for the individual level social distancing involves non-contact greetings, keeping distance of at least one meter between two individuals, staying home or self-isolating even with mild symptoms such as fever, cough, headache until recovery, and avoiding crowded places. As for the community level social distancing involves closure or postponement of mass-gatherings including schools, public sectors, and social and sports events. Furthermore, it is important to make sure that people follow good respiratory hygiene such as cough and sneeze etiquettes to avoid contact with the virus.

Contact authorities for help

Seeking medical attention and contacting to the local health authority as soon as possible, can reduce the transmission of the infection. National and local authorities have the most up-to-date information regarding the COVID-19 situation of the respective area. Contacting in advance will allow the health-care provider to direct the patients to the nearest health-care facility without any delay. Contact to the authorities for help when:

- you or someone you know has fever, cough, chills or other respiratory symptoms.
- you or someone you know has been in contact with a patient who is suspected or has tested positive with COVID-19.
- you or someone you know has respiratory symptoms and had been travelling to COVID-19 highly affected areas.

This will also protect the patient from the illness and help prevent spreading the virus into the community.

Measures at the Community and Nation Levels

SARS-CoV-2 is currently spreading, sometimes subclinically, with high transmissibility among susceptible populations around the world, creating an important public health concern. Neither vaccines nor specific treatment are currently available to prevent or cure COVID-19. The key strategies to control SARS-CoV-2 in the community involve controlling the infection in order to slow its transmission by preventing amplification events and further spread there by protecting susceptible people. Environmental contamination (fomites) influence the spread of infectious diseases, environmental cleaning and disinfection are fundamental for COVID-19 prevention and control. Compounding the problem, the incubation time for COVID-19 is approximately 5-6 days, with presymptomatic infectiousness and increased viral excretion upon appearance of symptoms. Better coordination of quick case detection along with immediate implementation of traditional non-pharmaceutical interventions such as isolation, confinement, tracing all contacts and medical observation of COVID-19 patients and suspected cases, and social distancing are successful ways to limit its spread. When implemented early in accordance with the local context and complementary to individual prevention measures, these containment measures reduce the number of super-spreading events, slow virus amplification and greatly reduce virus spread from symptomatic and non-symptomatic cases as observed in Singapore, Hong Kong and China.

SARS-CoV-2 is transmitted by respiratory droplets and therefore requires certain proximity among people for its effective transmission. Limiting individual interactions and physical distancing between individuals can interrupt its transmission and subsequent virus amplification. There is no clear distinction in social distancing,
quarantine or landlock with significant movement restrictions for everyone. At the national level, governments implement community-wide containment (e.g., restrictive lock-down policies) in addition to non-pharmaceutical public health measures\textsuperscript{1,81}. In practice, these measures allow the separation of sick people with contagious diseases from uninfected ones and allow individuals follow-ups\textsuperscript{81}. Ethically, such measures challenge individual human rights and have major economic consequences\textsuperscript{21,81}. Therefore, it is important for science-based public health education to provide the reasons for quarantine or landlock, as well as to provide comfort and practical advice in order to prevent or reduce anxiety and distress\textsuperscript{22,95}. This implementation requires partnerships and cooperation with law enforcement at the local and national levels, often involving checkpoints, and may require legal sanctions for breaching quarantine\textsuperscript{21,81}. Community quarantines are currently underway in COVID-19 affected countries worldwide on an order of a magnitude that humanity has never known\textsuperscript{81}.

**Conclusion**

After the emergence of COVID-19 at the end of 2019, the disease has spread all over the world, recording nearly 5.5 million cases and more than 34 thousand deaths as of 26 May 2020. Many of the countries implemented strong control strategies such as lockdown and ban on international human movement as measures of containment of COVID-19. Even so, cases and deaths are increasing day by day. Humans now confront a threat which is similar to that of the "Spanish flu" during 1918 to 1919, about a century ago. Since the COVID-19 pandemic may continue or repeat for a long period of time, it is crucially important to know what counter measures are effective. Though several candidates of vaccines and drugs are being developed, no effective vaccine or therapeutic drug exists so far.

Under such conditions, we should re-evaluate general hygiene practices as the measures to prevent COVID-19. Since the main transmission routes of SARS-CoV-2 are droplets and contact, reducing virus loads in these transmission routes should result in decreased chance of infection. There is a controversy whether wearing a mask is effective to prevent the infection. Human seasonal coronavirus from the infected individuals can be effectively filtered by a surgical mask\textsuperscript{45}. Therefore, it is highly possible that community-wide wearing of face masks can reduce the total number of infections in the community\textsuperscript{50}. To prevent droplet spread, the effect of wearing a mask should be further emphasized. Proper hand hygiene through washing hands and using hand sanitizers can reduce the possibility of virus transfer from contaminated hands to susceptible organs such as eyes and mouth. Social distancing which is related to changing behaviors is also effective: avoiding shaking hands, or hugging for greetings and staying at home whenever possible may also reduce the chance of infection. Combining these general hygiene practices at the individual level may enhance the protection efficacy.

Finding appropriate measures to control COVID-19 at the community and nation levels is essential for reducing the number of cases and deaths. Some countries are implementing strong strategies, like lockdowns, while others are relying on controlling clusters of infection. Since variety of strategies have been implemented, and some countries seem to have succeeded in controlling the first wave of COVID-19, a large epidemiological survey should be conducted to identify the appropriate approaches.

One of the unique features of SARS-CoV-2 infection argued is to cause the subclinical infection, and, thereby, it produces the asymptomatic careers of the virus, which would play a critical role of disease spread widely\textsuperscript{80}. Calculation of the sero-positivity in the population is important to understand the disease dynamics more precisely and to estimate the probability to acquire high level of herd-immunity enough to halt the epidemic.
Infection of SARS-CoV-2 in animals should also be more investigated to assess the risk of COVID-19 in animals. Since SARS-CoV-2 can infect domestic cats and dogs\textsuperscript{65, 66}, the significance of companion animals for virus transmission to humans should be urgently clarified. SARS-CoV-2 may have originated from bat species but more surveys are required. It is also unknown whether SARS-CoV-2 has intermediate host species. Identification of the natural host is a base of control of zoonoses, which can be transmitted among humans and animals including COVID-19 and elucidate the route of transmission from the original host animal(s) to humans. Moreover, surveillance of wild animals should be strengthened to seek for potential pathogens in humans. As zoonotic events occurred at human-animal interface, research activities and control measures for zoonoses would be implemented under the One Health Concept.

Many challenges remain to be revealed in SARS-CoV-2 and COVID-19. The efforts to understand the virus, the disease, and the epidemiology at multi-sectional levels can minimize the social damage caused by COVID-19.

Acknowledgements

We would like to thank whole of the team members and their supervisors contribute their effort to completing this review paper. Ms. Precious Bwalya, Mr. Chizimu Yamweka Joseph, Ms. Mai Kishimoto, Mr. Vuong Tuan Phong, Ms. Chayada Piantham, and Mr. Misheck Shawa, participated in summarizing the contents. Mr. Michael Henshaw contributed to proof-reading of the draft. Prof. Motohiro Horiuchi organized this team.

Reference


10) Cave AJE. The evidence for the incidence of tuberculosis in ancient Egypt. British


54) Nikkei Asian Review. Taiwan's battle against


---

Taishi Kidaka, Sithumini M.W. Lokupathirage, Bungiriye Devinda Shameera Muthusinghe, Boniface Lonke Pongombo, Christida Estu Wastika, Zhouxing Wei et al.


83) Wolfel R, Corman VM, Guggememos W, Seilmaier M, Zange S, Muller MA, Niemeyer D, Jones TC, Vollmar P, Rothe C, Hoelscher


The swab-sampled dry fecal cytology in healthy dogs and in dogs with acute and chronic diarrhea: a pilot study

Elena Benvenuti 1), Enrico Bottero 2), Alessio Pierini 1,*) Eleonora Gori 1) and Veronica Marchetti 1)

Abstract
Dry-mount fecal cytology is a little explored procedure that is potentially useful for dogs with gastrointestinal diseases. This study describes fecal cytology using swab sampling in healthy dogs (HD) and in dogs with acute and chronic diarrhea. Forty HD, 40 dogs with acute diarrhea (AD; diarrhea < 5 days) and 40 dogs with chronic diarrhea (CD; diarrhea > 3 weeks) were also enrolled. Sixteen different cytological features were scored for each fecal sample. Twenty HD were used to establish normal reference range for each cytological feature. Exact tests were used to evaluate associations between the three groups. The presence of red blood cells, cocci bacterial monomorphism and spore-forming bacteria were significantly higher in AD than the HD. Neutrophils, lymphocytes and macrophages were significantly higher in AD and CD groups compared to HD. Plasma cells were significantly higher in CD and the HD and AD groups. Bacterial phagocytosis was significantly higher in AD group than CD and HD. In conclusion, swab-sampled fecal cytology, as a cheap and feasible procedure, can be a useful diagnostic and monitoring technique. Although, our pilot study results showed differences between HD and enteropathic dogs, further investigations are necessary.

Key Words: canine, diarrhea, dry-mount fecal cytology, rectal swab

Introduction
Fecal cytology (FC) is used for fecal examination in dogs with gastrointestinal symptoms 2,9). There are two types of FC: wet-mount FC and dry-mount fecal cytology (DFC). Wet-mount FC consists of the microscopic observation of a fresh stool smear, which ideally is less than five minutes old. Wet-mount FC is suitable for the detection of Giardia spp., trichomonides and amoebeae, as well as larvae of nematodes (e.g., Strongiloides spp.) and bacteria such as Campylobacter spp. 2,4). With DFC, the smear can be collected by various sampling methods 4) (e.g., rectal scraping, rectal lavage and digital examination) and then is air dried and stained. This method is useful for identifying infectious agents (e.g., Prototheca spp., Cryptococcus spp.), inflammatory or neoplastic cells, and for evaluating the cytological features of the intestinal microbiota 2,5,8,10).

In the DFC of healthy dogs (HD), an extremely polymorphic population of several different bacilli
Table 1. Scoring system for fecal cytological feature evaluation.

<table>
<thead>
<tr>
<th>Cytological features</th>
<th>Power field</th>
<th>Category</th>
</tr>
</thead>
<tbody>
<tr>
<td>Squamous cells</td>
<td>10×</td>
<td>Normal: &lt;50</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Abnormal: ≥50</td>
</tr>
<tr>
<td>Columnar cells</td>
<td>10×</td>
<td>Normal: &lt;20</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Abnormal: ≥20</td>
</tr>
<tr>
<td>Neutrophils</td>
<td>10×</td>
<td>Normal: &lt;5</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Abnormal: ≥5</td>
</tr>
<tr>
<td>Eosinophils</td>
<td>10×</td>
<td>Normal: &lt;10</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Abnormal: ≥10</td>
</tr>
<tr>
<td>Lymphocytes</td>
<td>10×</td>
<td>Normal: &lt;10</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Abnormal: ≥10</td>
</tr>
<tr>
<td>Plasma cells</td>
<td>10×</td>
<td>Normal: &lt;5</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Abnormal: ≥5</td>
</tr>
<tr>
<td>Macrophages</td>
<td>10×</td>
<td>Normal: &lt;5</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Abnormal: ≥5</td>
</tr>
<tr>
<td>Immature lymphoid cells</td>
<td>10×</td>
<td>Normal: &lt;10</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Abnormal: ≥10</td>
</tr>
<tr>
<td>Red blood cells</td>
<td>40×</td>
<td>Absent</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Present</td>
</tr>
<tr>
<td>Cyniclomyces spp</td>
<td>40×</td>
<td>Normal: &lt;10</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Abnormal: ≥10</td>
</tr>
<tr>
<td>Yeasts</td>
<td>40×</td>
<td>Normal: &lt;30</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Abnormal: ≥30</td>
</tr>
<tr>
<td>Presence of cocci bacterial monomorphism*</td>
<td>100×</td>
<td>Absent</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Present</td>
</tr>
<tr>
<td>Gull-wing-shaped bacteria</td>
<td>100×</td>
<td>Normal: &lt;5</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Abnormal: ≥5</td>
</tr>
<tr>
<td>Spiral-shaped bacteria</td>
<td>100×</td>
<td>Normal: &lt;5</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Abnormal: ≥5</td>
</tr>
<tr>
<td>Spore-forming bacteria</td>
<td>100×</td>
<td>Normal: &lt;5</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Abnormal: ≥5</td>
</tr>
<tr>
<td>Bacterial phagocytosis</td>
<td>100×</td>
<td>Normal: Absent</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Present</td>
</tr>
</tbody>
</table>

For cytological features observed with a 10× magnification, all the smear was examined.
For cytological features observed with a 40× and 100× magnification, ten random fields were examined.
* More than 50% of cocci bacteria

is typically observed⁴. There should be fewer than five spore-forming rods/100× field, and cocci should be rare or absent⁵,⁶,¹¹. Occasionally, a low number of individual or doublet Cyniclomyces spp. may be observed, but its real pathogenic power is still unclear⁴,⁶,¹¹. A monomorphic or oligomorphic bacterial population, an increased number of cocci or an increased amount of yeast (e.g., Candida, Cyniclomyces spp.) are found in dysbiosis¹¹. The presence of neutrophils is abnormal and may be associated with distal colitis or proctitis⁵,¹¹. Fecal cytological patterns in HD have already been reported using several cytological sampling techniques⁴. In Frezoulis' study, FC features collected by various methods, including digital examination (DE), rectal scraping (RS) and rectal lavage (RL) in HD and dogs with diarrhea, are described. In HD, the median number of isolated epithelial cells and lymphocytes was higher when RS was used. This may be because RS is a more aggressive procedure compared to DE and RL, and may collect greater numbers of lymphocytes from the colic lymphoid follicles and columnar epithelial cells from the mucosa⁴. RS may be preferable when the deeper mucosal layers need to be sampled, such as for the diagnosis of colorectal lymphoma⁴. In dogs with diarrhea, the median cluster of epithelial cells and the number of neutrophils in fecal samples have been found to be different among sampling methods. In particular, the presence of clusters of epithelial cells and neutrophils have been shown to be more frequent in RS than in DE and RL⁴. Since there are no available data on swab-sampled DFC on both healthy dogs and dogs with acute and chronic diarrhea, the first aim is to describe swab-sampled DFC features in these populations. In addition, since our second hypothesis is that in dogs with acute and chronic diarrhea may have different various population of inflammatory cells one of each other and different compared to healthy dogs, the second aim is to evaluate potential differences in swab-sampled
DFC between the three study populations.

**Materials and Methods**

**Healthy dogs**

Twenty HD were initially used to determine the reference range for each cytological feature (Table 1, column “normal”). A control group was recruited from HD identified during routine physical examination for vaccination. In all dogs, a DFC via rectal swab was performed. A plastic swab was moistened with sterile saline solution, inserted in the rectal ampulla with an inclination of 45° for 1 to 4 cm (according to the size of the patient), rotated on the mucosal surface for 4-5 times, extracted and rolled onto glass slides for cytology. The rectal swab was always performed by the same operator and only one smear for each patient was performed. All smears were stained with a Romanowsky stain (Diff Quik® Bio Optica Milano S.p.A.- Milan, Italy) and examined by a cytopathologist using a light-microscope (Leica DM LB Microscope, Leica Microsystems Srl, Milan, Italy). The highest number for each specific cytological feature detected in the first HD was used as the upper limit of the reference range for that cytological feature. Regarding *Cyniclymeces* spp.*, gull-wing-shaped
bacteria\textsuperscript{2,10}, spiral-shaped bacteria\textsuperscript{1,11} and yeasts\textsuperscript{13}, previously published reference ranges were used. All patients were evaluated using a scoring system established for 16 cytological features (Table 1). The entire smear was evaluated at 10× to estimate the amount of squamous and columnar cells, neutrophils, eosinophils, lymphocytes, plasma cells, macrophages and immature lymphoid cells. The *Cyniclomyces* spp. is a yeast and morphologically identified by its “spectacle case” shape; the length is approximately 1/5\textsuperscript{th} of the diameter of a *Toxocara canis* egg.\textsuperscript{6} Presence of red blood cells (RBCs) and number of *Cyniclomyces* spp. and other round-shape yeasts were assessed at 40× magnification in 10 random fields (Table 1). Presence of cocci or rod-shaped bacterial monomorphism and bacterial phagocytosis (Fig. 1-a) and the number of gull-wing-shaped bacteria, spiral-shaped bacteria and spore-forming bacteria were evaluated at 100× magnification in 10 random fields. Cocci bacterial monomorphism was evaluated when cocci exceeded 50% in 10 random fields. (Table 1; Fig. 1-b).

**Dogs with acute and chronic diarrhea**

Client-owned dogs were enrolled with a diagnosis of acute diarrhea (AD) and chronic diarrhea (CD) that had been referred to our internal medicine service. For each dog, signalment and clinical history were collected and signed informed consent was obtained from their owners. The AD group included dogs with a history of diarrhea for less than five days. The CD group included dogs with a history of diarrhea for at least three weeks. Each CD dog had a hematobiochemical profile, urinalysis, fecal panel and diagnostic imaging performed as a part of routine care. In CD dogs other extra-intestinal diseases, infectious or parasitic diseases and intestinal disease of other etiology (e.g., mechanical obstruction from intussusception, foreign body or intestinal tumors) were ruled out. In all patients, FC was performed at admission or at the time of endoscopy before anesthesia was induced. Dogs with positive fecal flotation or positive in-clinic Giardia test (SNAP\textsuperscript{®} Giardia test, Idexx Laboratories Inc. Europe, Hoofddorp, Netherlands) were excluded. In both groups, administration of symptomatic treatment (spasmolytic, adsorbent, antiemetic or antacid drugs and probiotics) and flea and tick preventive drugs were permitted. In the AD group, dogs already on antibiotic therapy were excluded. In the CD group, antibiotics, probiotics and immunosuppressive drugs had to have been discontinued at least ten days before the endoscopy. Each dog in CD group had a final diagnosis of chronic lymphoplasmacytic enteritis confirmed at the histopathologic evaluation. Dogs with intestinal lymphoma and with colorectal neoplasia were excluded.

Normal fecal cytological scores were obtained from the HD. The age of the three groups were tested with the D’Agostino Pearson normality test and then compared between the three groups using Kruskal-Wallis test. Fecal cytological features were compared between the three study populations using Chi-square test and then compared between the three pairs of groups (HD vs. AD, HD vs. CD, AD vs. CD) using Fisher’s exact test. A *P*-value < 0.05 was considered significant (GraphPad Prism 7 for Windows, La Jolla, CA).

**Results**

One hundred and twenty dogs were enrolled and divided into three groups. Forty dogs were included in the HD group, 40 in the AD, and 40 in the CD group. The median age for all dogs was six years (range 1-17 years) and was similar to the three study groups (HD, AD and CD; *P* > 0.05). Fifty-six female dogs (17 spayed) and 64 male dogs (4 neutered) were included in this study and distribution of sex and sexual status was similar between all groups.

Of the 120 dogs included in the study, 51 were mix-breed. The involved breeds were: German Sheperd (13), Labrador Retriever (6), English Setter (5), Cavalier King Charles Spaniel (4), Cocker Spaniel (4), Golden Retriever (3), Jack Russel Terrier (3), West Highland White Terrier...
Table 2. Fecal cytological scores for each parameter observed in the three study groups.

<table>
<thead>
<tr>
<th>Cytological parameters</th>
<th>HD</th>
<th>AD</th>
<th>CD</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Presence of RBC</td>
<td>0/40 (0%)A</td>
<td>11/40 (27.5%)B</td>
<td>4/40 (10%)A</td>
<td>0.0008</td>
</tr>
<tr>
<td>Squamous cells</td>
<td>0/40 (0%)</td>
<td>0/40 (0%)</td>
<td>0/40 (0%)</td>
<td>NE</td>
</tr>
<tr>
<td>Columnar cells</td>
<td>0/40 (0%)</td>
<td>0/40 (0%)</td>
<td>0/40 (0%)</td>
<td>NE</td>
</tr>
<tr>
<td>Neutrophils</td>
<td>0/40 (0%)A</td>
<td>36/40 (90%)B</td>
<td>29/40 (72.5%)B</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Eosinophils</td>
<td>0/40 (0%)</td>
<td>2/40 (5%)</td>
<td>2/40 (5%)</td>
<td>0.3554</td>
</tr>
<tr>
<td>Lymphocytes</td>
<td>0/40 (0%)A</td>
<td>7/40 (17.5%)B</td>
<td>14/40 (35%)B</td>
<td>0.0002</td>
</tr>
<tr>
<td>Plasma cells</td>
<td>0/40 (0%)A</td>
<td>3/40 (7.5%)A</td>
<td>14/40 (35%)B</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Macrophages</td>
<td>1/40 (2.5%)A</td>
<td>9/40 (22.5%)B</td>
<td>12/40 (30%)B</td>
<td>0.004</td>
</tr>
<tr>
<td>Immature lymphoid cells</td>
<td>0/40 (0%)</td>
<td>1/40 (2.5%)</td>
<td>1/40 (2.5%)</td>
<td>0.6014</td>
</tr>
<tr>
<td><em>Cyniclomyces guttulatus</em></td>
<td>1/40 (2.5%)</td>
<td>1/40 (2.5%)</td>
<td>3/40 (7.5%)</td>
<td>0.4340</td>
</tr>
<tr>
<td>Yeasts</td>
<td>14/40 (35%)</td>
<td>12/40 (30%)</td>
<td>15/40 (37.5%)</td>
<td>0.7716</td>
</tr>
<tr>
<td>Presence of cocci bacterial monomorphism</td>
<td>0/40 (0%)A</td>
<td>12/40 (30%)B</td>
<td>4/40 (10%)A</td>
<td>0.0003</td>
</tr>
<tr>
<td>Gull-wing-shaped bacteria</td>
<td>0/40 (0%)A</td>
<td>5/40 (12.5%)A</td>
<td>0/40 (0%)A</td>
<td>0.0054</td>
</tr>
<tr>
<td>Spiral-shaped bacteria</td>
<td>0/40 (0%)</td>
<td>1/40 (2.5%)</td>
<td>1/40 (2.5%)</td>
<td>0.6014</td>
</tr>
<tr>
<td>Spore-forming bacteria</td>
<td>2/40 (5%)A</td>
<td>9/40 (22.5%)B</td>
<td>2/40 (5%)A</td>
<td>0.01</td>
</tr>
<tr>
<td>Bacterial phagocytosis</td>
<td>0/40 (0%)A</td>
<td>25/40 (62.5%)B</td>
<td>9/40 (22.5%)B</td>
<td>&lt;0.0001</td>
</tr>
</tbody>
</table>

AD = acute diarrhea; CD = chronic diarrhea; HD = healthy dogs; NE = not evaluable; RBC = red blood cell. Fecal cytological scores for each feature were analyzed with Chi-square test between the three groups and if *P* < 0.05 was considered significant. A, B, C, two groups with different letters have a statistically significant difference in the post-hoc Fisher’s exact test.

The presence of RBCs, cocci bacterial monomorphism and spore-forming bacteria were significantly different between the HD and AD groups (*P* = 0.0004, *P* = 0.0002 and *P* = 0.0476, respectively). HD dogs had significantly different neutrophils, lymphocytes (Fig. 1-c) and macrophages both compared to AD (*P* < 0.0001, *P* = 0.0117, *P* = 0.0143, respectively) and CD groups (*P* < 0.0001, *P* < 0.0001 and *P* = 0.0009, respectively). Plasma cells were significantly different between CD and the HD and AD groups (*P* < 0.0001 and *P* = 0.0052, respectively; Fig. 1-d). Gull-wing-shaped bacteria and bacterial phagocytosis were significantly different between the three groups (*P* = 0.0054 and *P* < 0.0001, respectively). However, gull-wing-shaped bacteria scores were compared between pairs of groups and showed no significant differences. Bacterial phagocytosis scores were significantly different between the three groups (HD,
vs AD $P < 0.0001$, HD vs CD $P = 0.0024$, AD vs CD $P = 0.0006$, respectively). Data regarding the scores of each individual cytological feature are shown in Table 2.

**Discussion**

Dry-mount fecal cytology is not commonly used in clinical practice. To date, few studies have described the technique and interpretation of results\(^2,4\).

In the present study, RBCs and inflammatory cells were absent in HD. In a recent study on thirty-seven healthy dogs, neutrophils and lymphocytes were detected when fecal cytology was collected by DE and RS, however, when RL was used, no RBCs and inflammatory cells were identified in the sample\(^4\). These findings suggested that more aggressive procedures, such as DE and RS, can lead to falsely increased blood-derived cell levels, making the interpretation of results challenging. In the present study, fecal cytological samples were collected using a moistened plastic swab, which, in the authors’ opinion, may be less traumatic than DE and RS, thus reducing the risk of over-diagnosing inflammatory disease or intestinal hemorrhage using FC. In our study, the presence of inflammatory cells in swab-sampled DFC was associated with an intestinal inflammatory condition. According to Mandigers et al., the presence of yeast is not associated to intestinal disease and both round-shape yeast and *Cyniclomyces* spp. can also be present in healthy dogs being its pathogenic role unclear\(^6\).

According to the literature, pleomorphic bacteria (a mixture of coccis and rods) in HD can been seen. As previously reported, our data confirm the microbiota in healthy dogs is variable with a pleomorphic population, with the rod component being the largest\(^5\).

In the present study, macrophages and spore-forming bacteria were detected only in one dog and two dogs of the HD group, respectively. This finding suggests that detection of a low number of macrophages and spore-forming bacteria should be interpreted with caution.

RBCs were significantly more frequently observed in the AD group. During acute enteropathies, RBCs are expected to be detected because hyperemia, inflammatory edema or direct damage of the colonic mucosa are usually present in such conditions\(^12\). However, in our study population cytologic signs of acute (erythrophagocytosis) or chronic hemorrhage (hemosiderin phagocytosis) were not present.

In our study, neutrophils, lymphocytes and macrophages were significantly increased in dogs with enteropathy compared to HD. Thirty-six out of 40 (90%) dogs in the AE group showed the presence of neutrophils, 25 out of 40 (60%) showed bacterial phagocytosis, and 30% showed cocci bacterial monomorphism. These data suggest the presence of an acute inflammation, besides the involvement of bacteria in the pathological process. With rectal cytology it is not possible to determine whether bacteria are the primary cause or a consequence of the pathological process\(^1\). In our opinion, it would be interesting to study the associations between bacterial phagocytosis, clinical (e.g., fever) and clinical pathological (e.g., leukocytosis or toxic neutrophils) findings to direct further laboratory investigations (e.g., PCR, specific fecal culture for pathogenic bacteria, immune-enzyme assays for bacterial toxins).

The presence of gull-wing-shaped bacteria was different between groups (Table 2). However, their presence only in the AD group suggests a possible infectious etiology which may be investigated with the laboratory investigation reported above.

In addition, the presence of increased number of spore-forming bacteria in the AD group might warrant further investigations (e.g., *Clostridium perfringens* enterotoxins) into the role of these bacteria in this subset of dogs with acute diarrhea\(^7\).

The presence of small lymphocytes and macrophages was significantly associated with dogs with enteropathy, however the presence of plasma cells (35%) was the only cytological feature associated with CD. Chronic inflammatory
enteropathies are often characterized by the presence of a reactive proliferation of lymphocytes and plasma cells in the gastrointestinal mucosa and submucosa. Regarding inflammatory cells, a previous study described findings in FC in dogs with diarrhea, but no differences were observed between chronic and acute disease. In our case, the findings of plasma cells and bacterial phagocytosis were significantly different between the AD and CD groups.

These results highlight the importance for further studies about the utility of the DFC for the diagnostic work up in enteropathic dogs. This study has some limitations. Primarily, we did not evaluate the absolute number of cytological parameters, however a normal/abnormal basis was estimated from the fecal cytology of twenty healthy dogs. It is therefore not possible to obtain an absolute number in order to establish a ROC curve to determine the actual cut off for each parameter. Furthermore, some evaluations, such as cocci bacterial monomorphism, were a subjective estimation which may differ between cytopathologists. The lack of an etiopathological characterization of the enteropathies and particularly the lack of a clinical severity score, are further limitations of the present study, and therefore the real utility of DFC in clinical practice cannot be determined. On the other hand, since DFC is a cheap, fast and non-invasive procedure that can exclude some life-threatening infectious agents (e.g., *Prototheca* spp.), this pilot study is the first step to evaluate the clinical and diagnostic value of DFC.

**References**

11) Wamsley HL. Dry-mount fecal cytology. In:
Development of a highly sensitive method for the detection of Cryptosporidium parvum virus type 1 (CSpV1)

Ayman Ahmed Shehata¹², Hironori Bando¹, Yasuhiro Fukuda¹, Mohammad Hazzaz Bin Kabir³⁴, Fumi Murakoshi⁵, Megumi Itoh⁶, Atsushi Fujikura⁷, Hiroaki Okawa⁷, Takuto Endo⁸, Akira Goto⁹, Masayuki Kachi¹⁰, Toshie Nakayama¹¹, Yuto Kano¹², Shoko Oishi¹³, Konosuke Otomaru¹³, Kei Kazama¹⁴, Mohamed Ibrahim Essa² and Kentaro Kato¹³,*

¹Laboratory of Sustainable Animal Environment, Graduate School of Agricultural Science, Tohoku University, 232-3 Yomogida, Naruko-onsen, Osaki, Miyagi 989-6711, Japan
²Department of Animal Medicine, Infectious Diseases, Faculty of Veterinary Medicine, Zagazig University, El-Shohada, Moawwad, Qesm Awel AZ Zagazig, 44511, Egypt
³National Research Center for Protozoan Diseases, Obihiro University of Agriculture and Veterinary Medicine, Inada-cho, Obihiro, Hokkaido 080-8555, Japan
⁴Department of Microbiology and Parasitology, Sher-e-Bangla Agricultural University, Sher-e-Bangla Nagar, Dhaka-1207, Bangladesh
⁵Department of Infectious Diseases, Kyoto Prefectural University of Medicine, 465, Kajiicho, Kawaramachi-hiromoji, Kamigyoku, Kyoto 602-8566, Japan
⁶Department of Veterinary Medicine, Obihiro University of Agriculture and Veterinary Medicine, Inada-cho, Obihiro, Hokkaido 080-8555, Japan
⁷Fukuoka Dairy Cattle Artificial Insemination Clinic, Fukuoka Prefecture Dairy Farming Cooperative, 1-13-4, Susenji, Nishiku, Fukuoka, Fukuoka 839-0832, Japan
⁸Kurume Dairy Cattle Artificial Insemination Clinic, Fukuoka Prefecture Dairy Farming Cooperative, 75-2, Airaku, Ohashimachi, Kurume, Fukuoka 839-0832, Japan
⁹Veterinary Medical Center, Obihiro University of Agriculture and Veterinary Medicine, 2-11 Inada-nishi, Obihiro, Hokkaido 080-8555, Japan
¹⁰Dairy Research Department, Gifu Prefectural Livestock Research Institute, 1975-615 Kubohara, Yamaoka-cho, Ena, Gifu 509-7601, Japan
¹¹Miyazaki Agricultural mutual aid association, 17938-5 Nyuta Shintomi-cho, Miyazaki 889-1406, Japan
¹²Soo Agricultural mutual aid association, 2253 Osumicho Tsukino, Soo-shi, Kagoshima 899-8212, Japan
¹³Joint Faculty of Veterinary Medicine, Kagoshima University, 1-21-24 Korimoto, Kagoshima 890-0065 Japan
¹⁴School of Veterinary Medicine, Azabu University, 1-17-71 Fuchinobe, Chuo-ku, Sagamihara, Kanagawa 252-5201, Japan

Received for publication, February 4, 2020; accepted, April 22, 2020

*Corresponding author: Kentaro Kato, D.V.M., Ph.D
Laboratory of Sustainable Animal Environment, Graduate School of Agricultural Science, Tohoku University, 232-3 Yomogida, Naruko-onsen, Osaki, Miyagi 989-6711, Japan
Phone: +81-229-84-7391, Fax: +81-229-84-7391, E-mail: kentaro.kato.c7@tohoku.ac.jp
doi: 10.14943/jjvr.68.3.159
**Abstract**

*Cryptosporidium* is an apicomplexan zoonotic parasite that infects most mammals, including humans. *Cryptosporidium parvum* virus type 1 (CSpV1) is the first member within the Partitiviridae family recognized to infect protozoan hosts. *Cryptosporidium* tracking based on CSpV1 detection has been attempted; however, each study used different conditions for the PCR protocol, primers, and target viral sequences. Accordingly, the sensitivity of PCR-based CSpV1 detection remains unclear. In addition, oocyst purification from clinical samples can be problematic due to small number of oocysts, sample degradation and low yield efficiency of currently used purification methods. Here we show that the second half of the coding region of dsRNA2 can be detected from various types of clinical samples, without the need for oocyst purification, by using a semi-nested-PCR technique. Furthermore, we show that the short sequence targeted in this study has higher diversity than the *Cryptosporidium* GP60 gene. Taken together, our findings suggest that this method could be used as an important tracking marker for *Cryptosporidium* species.

**Key Words:** Calves, Cryptosporidium, CSpV1, PCR

**Introduction**

*Cryptosporidium* is a zoonotic parasite that causes cryptosporidiosis. *Cryptosporidium* can infect a wide range of hosts including domestic animals and humans through ingestion of contaminated food or water\(^{10}\). The severe diarrhoea and related high mortality associated with the infection in young animals have a serious impact on animal husbandry\(^4\). *Cryptosporidium* infection occurs throughout the world but high prevalence rates are more common in poorly developed countries where prevalence was ranged from 20% to 60% in individual calves in Japan and may reach to 98% at herd level in Argentina\(^1,12,22\). Unfortunately, none of the drugs currently available to treat cryptosporidiosis are completely effective\(^29\). Therefore, the development of a quick and accurate detection method and genetic surveillance of *Cryptosporidium* are particularly important to predict and prevent the spread of infection.

Cryptosporidium parvum virus type 1 (CSpV1), which is a double-strand (ds) RNA virus belonging to the Cryspo-virus genus in the Partitiviridae family, was first detected in 1997 from *C. parvum*\(^13,14\). So far, there have been no reports demonstrating the extracellular transmission of the virus to *Cryptosporidium* because CSpV1 is vertically transmitted intracellularly during *Cryptosporidium* division\(^25\). In addition, it has been reported that *Cryptosporidium* oocysts contain a large number of viral RNAs relative to the number of oocyst genes\(^31\). Therefore, CSpV1-based techniques have been developed as an alternative approach to *Cryptosporidium* detection and identification\(^17,33\).

In fact, the detection sensitivity of CSpV1-based techniques has been reported to be 2,000-fold higher than that of techniques designed to detect *Cryptosporidium* oocysts because of the stability and abundance of the viral RNA\(^15,31\). The virus possesses an encapsidated long dsRNA1 segment that encodes the RNA-dependent RNA
polymerase and a short dsRNA2 segment that encodes the capsid protein\(^{24}\). The complete sequences of the CSpV1 dsRNAs have been identified in *C. hominis*, *C. felis*, and *C. meleagridis* and have been shown to be conserved\(^{18}\). Therefore, dsRNA2 has frequently been used for *Cryptosporidium* detection. However, different regions within or outside the coding region of the dsRNAs have been used as the targets for PCR-based detection\(^{17-19}\), and the effects of differences in the PCR approaches used on the sensitivity of viral detection remain unknown.

Although CSpV1-based techniques show great potential for use in *Cryptosporidium* detection, the purification of *Cryptosporidium* oocysts remains an essential step for viral RNA extraction. Currently used methods for oocyst recovery appear to be unsuitable for samples with a small number of oocysts\(^{7, 28}\). Moreover, it has been reported that degradation of oocysts due to excystation or storage can lead to an extreme reduction in the efficiency of oocyst purification\(^{11}\). For these reasons, new methods that do not require *Cryptosporidium* oocyst purification are needed.

In the present study, we demonstrate that CSpV1 detection sensitivity is affected by the PCR target site within CSpV1 dsRNA2. In addition, we show that a partial dsRNA2 sequence of CSpV1 can be used to detect CSpV1 from clinical samples without the need for *Cryptosporidium* oocyst purification. Our data suggest that this method has potential as an alternative strategy for *Cryptosporidium* or CSpV1 detection and identification.

**Materials and Methods**

**Clinical sample collection:** A total of 62 diarrhoeic faecal samples were kindly provided by the veterinarians in various prefectures of Japan. Samples were from dairy and beef calves that ranged in age from 3 days to 50 days, acquired between October 2018 and March 2019, from eight different Japanese prefectures. In this study, three different breeds of calves were included: Holstein Friesians, Japanese Black, and cross-bred F1 hybrids. Samples were stored at \(-28^\circ\text{C}\) until use.

**RNA extraction from faecal samples:** RNA was extracted from all samples without oocyst purification by using 0.4–0.5 g of faeces according to the protocol of the Quick-RNA Faecal/Soil Microbe Microprep Kit (Zymo Research Corp, Irvine, CA, USA). RNA was stored at \(-80^\circ\text{C}\) until use. Some samples were examined microscopically for oocysts and were then subjected to at least three freezing-thawing cycles before RNA extraction.

**PCR protocol using RNA extracted from *C. parvum* HNJ-1 strain:** *C. parvum* HNJ-1 is maintained in nude mice in the Department of Infectious Diseases, Kyoto Prefectural University of Medicine, Japan. Total RNA was extracted from *C. parvum* HNJ-1 oocysts. In this study, we used seven sets of primer pairs for CSpV1 detection. The CPVS_ORF_1F and CPVS_ORF_6R primers were previously used for CSpV1 detection\(^{20}\). The other four primers were designed for this study. All of the primers used in this study are listed in Table 1. First, cDNA was synthesized by using 1000 pg of total RNA extracted from *C. parvum* HNJ-1 with the CPVS_ORF_1F primer by using the Thermo Scientific Verso cDNA Synthesis Kit (Thermo Scientific, Waltham, Massachusetts, CA, USA) according to the manufacturer’s instructions. The resulting cDNA was included the in initial and semi-nested

### Table 1. Different primer sequences used in this study.

<table>
<thead>
<tr>
<th>Primer</th>
<th>Sequence</th>
</tr>
</thead>
<tbody>
<tr>
<td>P1F</td>
<td>5’-ATTACAAGTGTGGAATCAATAGAG-3’</td>
</tr>
<tr>
<td>P2F</td>
<td>5’-CTATGCACCATAGTGGAATTAC-3’</td>
</tr>
<tr>
<td>P3F</td>
<td>5’-CTATCGCTGAGCATAGCATACTAGATGG-3’</td>
</tr>
<tr>
<td>P4R</td>
<td>5’-ACTAACAGATGGCAGCGCTTCCG-3’</td>
</tr>
<tr>
<td>P5R</td>
<td>5’-CTGGGCTACACTCCGTCGTTACTAT-3’</td>
</tr>
<tr>
<td>P6R</td>
<td>5’-ATGGGACGCCATCTCAGCTACAC-3’</td>
</tr>
</tbody>
</table>

...
DETECTION OF CRYPTOSPORIDIUM PARVUM VIRUS TYPE 1

PCR reaction, which was performed by using the KOD FX Neo kit with the indicated primer pairs (Fig. 1A). Then, to evaluate the sensitivity of our protocol, the same procedure was repeated using four different concentrations (10, 1, 0.1, and 0.01 pg/ul) of template total RNA extracted from C. parvum HNJ-1 for cDNA synthesis and amplification of the various target fragments. The PCR protocol was as follows: 94 °C for 2 min, then 45 cycles of 98 °C for 10 s, 60 °C for 30 s and 68 °C for 1 min, followed by 68 °C for 7 min.

Semi-nested PCR protocol using RNA extracted from faecal samples: After optimization of our protocol using RNA from the C. parvum HNJ-1 strain, we examined the ability of this method to detect CSpV1 dsRNA2 from total RNA directly extracted from 62 faecal samples of calves in the field. Total RNA was extracted from these faecal samples as above. cDNA synthesis and the initial PCR, using primer pair 2, were carried out by using the protocol just described. Then, 2 μl of the first PCR product was used for the second PCR reaction, which was performed by using the KOD FX Neo kit (TOYOBO, Osaka, Japan) with the indicated primer pair 6. The PCR protocol was as follows: 94 °C for 2 min, then 45 cycles of 98 °C for 10 s, 60 °C for 30 s and 68 °C for 1 min, followed by 68 °C for 7 min.

Detection and visualization of CSpV1 and Cryptosporidium genetic diversity: PCR products were separated by electrophoresis through 1.5 % agarose gels and extracted by
using the NucleoSpin Gel and PCR Clean-up kit (MACHEREY-NAGEL GmbH & Co, Düren, Germany) according to the manufacturer’s instructions. An automated sequencer (Applied Biosystems 3130xl Genetic Analyzer; Applied Biosystems, Tokyo, Japan) was used for analysing sequences. The resulting sequences were read on 4Peaks Genetic Analyzer software and aligned using Clustal W on the MEGA7 program. The aligned dsRNA2 sequences in which all gaps were eliminated were applied to the popART software to visualize genetic diversity by nucleotide substitutions\(^2\). Similarly, GP60 gene sequences (published data) for the same twenty-five samples were used to construct haplotype networks to be compared with the dsRNA2-based tree.

**Results**

The PCR target region of CSpV1 has an effect on virus detection sensitivity

To test the PCR amplification efficiency in relation to the PCR conditions, we used 1 ng of RNA extracted from purified *Cryptosporidium parvum* oocysts and different primer pairs targeting dsRNA2 (Fig. 1A). We found that...
CSpV1 was only detected by primer pairs targeting the second half of dsRNA2 (i.e., primer pairs 4, 5, 6, or 7; Fig. 1B). The specificity of each primer pair was confirmed through amplicon sequencing. Additionally, whereas primer pairs 5 and 7 showed non-specific amplification, specific amplicons were clearly produced by primer pairs 4 and 6 (Fig. 1B). Therefore, we next tested the limit of detection of CSpV1 by using low RNA concentrations from *C. parvum* oocysts and primer pair 4 or 6 (Fig. 1C). We found that CSpV1 was strongly detected by primer pair 6 compared with primer pair 4 (Fig. 1C). Taken together, these data indicate that both the viral target sequence and the primer pair combination are important for CSpV1 detection.

Establishment of a direct method for the detection of CSpV1 from faecal samples

*Cryptosporidium* oocyst purification has been essential for sensitive molecular or serological CSpV1 detection \(^{(17, 20)}\), even though the current purification procedures have limitations and drawbacks. Therefore, we assessed whether a PCR-based CSpV1 detection method using primer pair 6 could be used to assess faecal samples without having to purify the *Cryptosporidium* oocysts (Fig. 2A, 2B, 2C, and 2D). Storage conditions reportedly affect the extraction efficiency of RNA \(^{(11)}\). We confirmed that the extraction efficiency of RNA from faecal samples was markedly reduced by repeat freeze-thawing (Fig. 2B). We tried to detect CSpV1 by using RNA extracted from damaged faecal samples (i.e., samples that had been freeze-thawed three times). However, we failed to detect CSpV1 from these samples even though *Cryptosporidium* infection was confirmed by using a nested-PCR.
method targeting *Cryptosporidium* 18S rRNA (Fig. 2C). Then, we examined whether a semi-nested PCR method, using primer pair 2 for the first PCR and primer pair 6 for the second PCR, could be used to test faecal samples without purification of the *Cryptosporidium* oocysts. By using this approach, we were able to confirm the presence of CSpV1 in the damaged faecal samples (Fig. 2C), thereby demonstrating that the semi-nested PCR method could directly detect CSpV1 in damaged faecal samples. To test the sensitivity of the semi-nested PCR method, we attempted to detect CSpV1 from faecal samples that were freeze-thawed at least once and were negative for the parasite by a nested-PCR method targeting *Cryptosporidium* 18s rRNA(Fig. 2D). Some of the samples were CSpV1-negative in this assay(Fig. 2D), suggesting that our method is highly specific. Other samples were CSpV1-positive (Fig. 2D), indicating that our method is more sensitive than the existing method. Taken together, our findings demonstrate that this direct CSpV1 detection method is effective for use with faecal samples.

**Direct methods to detect CSpV1 in clinical samples**

Our current study has shown that the semi-nested PCR method using primer pair 6 is highly sensitive for the detection of CSpV1 from faecal samples without the need for purification of *Cryptosporidium* oocysts (Fig. 3A). We, therefore, next investigated whether this method could be used to detect CSpV1 in 62 clinical samples...
that had undergone freeze-thawing at least once; these samples were collected in Japan between October 2018 and March 2019 (Fig. 3A). Although a previous study reported that 50 out of these 62 samples were Cryptosporidium-positive (personal communication), we found that 59 of the same 62 samples were CSpV1-positive (Fig. 3A). Importantly, we found that the CSpV1-positive samples matched completely with the Cryptosporidium 18S rRNA-positive samples (Fig. 3A). Thus, we detected an additional 9 CSpV1-positive samples among a total of 12 Cryptosporidium 18S rRNA-negative samples (Fig. 3A). These results demonstrate that our direct viral detection method is highly sensitive even for clinical samples.

CSpV1 is present in C. bovis and C. ryanae

To date, CSpV1 has been reported in only four Cryptosporidium species: C. parvum, C. felis, C. hominis, and C. meleagridis\(^\text{17, 18}\). Our results suggest that CSpV1 is also present in C. bovis and C. ryanae (Fig. 3B). This is the first report to detect CSpV1 both in C. bovis and C. ryanae, suggesting that our method can detect CSpV1 regardless of the Cryptosporidium species (Fig. 3B). Moreover, we found a high number of CSpV1-positive samples in all breeds of beef and dairy calves (Fig. 3C), suggesting that our method can detect CSpV1 regardless of the cattle breed. These results demonstrate that our direct viral detection method can be used regardless of parasite species or host breed.

CSpV1 partial sequences show a high level of genetic polymorphism compared with Cryptosporidium GP60

Although the GP60 gene is frequently used for subtyping Cryptosporidium parvum, the C. parvum subtype IIA15G2R1 is the most common subtype found in cattle in many countries\(^\text{19}\) and is the only subtype of C. parvum that has been detected in Japan\(^\text{1, 3}\). In a previous study, the Cryptosporidium infection rate was about 80% where C. parvum isolates represented 92% of the total positive samples with IIA15G2R1 as the most common subtype (personal communication). In contrast, previous reports have shown variation in the sequence of CSpV1 dsRNA2\(^\text{17, 33}\). In one study, although 64 of 80 samples were found to be C. parvum-positive, GP60 gene sequences were obtained from only 41 samples (personal communication), and only 25 samples were found to express both the GP60 gene and partial CSpV1 dsRNA2 from these samples (Fig. 4A). We found that 24 of the 25 GP60 gene sequences comprised one group, whereas the other group contained only one sequence. In contrast, we obtained seven CSpV1 dsRNA2 variant groups based on the virus sequences: 2 groups contained one sequence, whereas the other 5 groups contained 2, 3, 4, 5, and 9 sequences, respectively. These results suggest that CSpV1 dsRNA2 sequences have greater genetic diversity than the GP60 gene sequence, even though the viral target sequence is shorter (Fig. 4A). Four nucleotide substitutions were found within the dsRNA2 target sequences; as a result, distinct nucleotide alignments were obtained and the samples could be clustered into 7 groups (Fig. 4B). Specifically, these 4 nucleotide substitutions at base pair positions 336, 465, 687, or 753 of the dsRNA2 target sequence are responsible for genetic diversity of the virus (Fig. 4B). In addition, virus sequences recovered from C. bovis-infected samples were 100% identical to each other and belonged to group (iii). Similarly, nucleotide sequences of CSpV1 for C. ryanae showed complete identity and clustered within group (iv) (Fig. 4A, 4B). However, the GP60-based sequence network revealed identical sequences with only one C nucleotide replaced with A at base pair positions 395. Taken together, these findings indicate that the partial dsRNA2 sequence that we targeted in this study could serve as an important tracking marker for C. parvum.
Discussion

In the present study, we demonstrated that a PCR method targeting a partial sequence of CSpV1 dsRNA2 can be used for virus detection from *Cryptosporidium* oocysts. Previous studies have shown that a PCR-based CSpV1 detection method has advantages for sensitive detection of *Cryptosporidium*, for example, detection of fewer than 5 oocysts have been reported\(^\text{19}\). However, these studies used various detection conditions, including various PCR protocols, different target regions of the viral RNA, and different primer pairs. Accordingly, the relationship between the efficiency of virus detection and the detection method has remained unclear. In the present study, we found that PCR amplification efficiency is specific for the target region of the viral RNA; whereas the first half of dsRNA2 is difficult to detect, the second half of dsRNA2 is effectively amplified by PCR. In addition, the 3-prime end of the coding sequence can lead to non-specific amplification, possibly because the first half of dsRNA2 contains a highly AT-rich region. In the present study, we clearly demonstrated that the second half of dsRNA2, which lacks the 3-prime end of the coding sequence, is effectively amplified by using our PCR method.

It has been reported that 100 μg of total RNA can be extracted from \(10^9\) *Cryptosporidium* oocysts\(^\text{28}\). Given that one *Cryptosporidium* oocyst contains 0.1 pg of total RNA, CSpV1 RNA may be present as less than 0.1 pg in one oocyst. Our study showed that 0.01 pg of RNA extracted from a *Cryptosporidium* oocyst is enough for CSpV1 detection, suggesting that our method has the potential to detect a single oocyst. Moreover, it has been reported that a short-conserved region within dsRNA2 is shared among all known virus sequences that have been identified in different *Cryptosporidium* species\(^\text{18}\). Importantly, amplicons produced by our method include this conserved region, which suggests that our method may be useful for tracking sources of *Cryptosporidium* outbreaks.

Most previous CSpV1 detection studies used RNA extracted not from faeces but from oocysts\(^\text{17, 20}\). However, it is difficult to purify *Cryptosporidium* oocysts from the faeces of hosts with a low oocyst load\(^\text{3}\). In addition, degradation of oocysts due to excystation or storage can result in a significant decrease in the efficiency of purification of *Cryptosporidium* oocysts\(^\text{11}\). In fact, the PCR sensitivity with clinical faecal samples stored for 5 weeks was found to be less than 20\%\(^\text{11}\). Of note, our method successfully detected CSpV1 from clinical samples that had been stored for more than a year and subjected to frequent freezing-thawing cycles (at least one) before RNA extraction. Thus, we have established a highly sensitive method for CSpV1 detection from clinical samples without the need for purification of *Cryptosporidium* oocysts.

A previous study found that 50 out of 62 samples contained *Cryptosporidium* oocysts based on a *Cryptosporidium* 18S rRNA detection method (personal communication). In contrast, using our detection method, we demonstrated that 59 of those 62 samples are, in fact, CSpV1-positive. Importantly, these CSpV1-positive samples included the 50 *Cryptosporidium* 18S rRNA-positive samples, thereby demonstrating that our PCR method targeting the partial CSpV1 dsRNA2 can be used as an alternative *Cryptosporidium* detection method. Of interest, our current study identified 9 of the *Cryptosporidium* 18S rRNA-negative samples as CSpV1-positive, suggesting that CSpV1 may be a more sensitive marker of *Cryptosporidium* than the 18S rRNA gene of the *Cryptosporidium* genome. Some studies have reported that CSpV1-based methods show greater sensitivity in detecting *Cryptosporidium* in clinical samples than do techniques that use oocyst or sporozoite antigens; however, these studies involved serologic techniques or colloidal gold-based immunochromatographic tests\(^\text{15, 16, 31}\). In contrast, here we demonstrated that a PCR-based method targeting the partial CSpV1 dsRNA2 can detect for *Cryptosporidium* in clinical samples with high sensitivity. *Cryptosporidium* has been
is isolated all over the world including rural areas and developing countries. Improving PCR-based CSpV1 detection methods for use with clinical samples that have been preserved is important, because such methods are widely applicable for tracking of Cryptosporidium infections. Thus, our PCR-based method targeting the partial CSpV1 dsRNA2 could contribute to various characterization studies of Cryptosporidium without temporal and spatial constraints.

Although 29 Cryptosporidium species have been recognized to date, CSpV1 has been reported in only four species: C. parvum, C. felis, C. hominis, and C. meleagridis. In the present study, we found CSpV1 in C. bovis and C. ryanae for the first time. The lack of information about CSpV1 in C. bovis and C. ryanae may be due to the pathology of these Cryptosporidium species; infection with these Cryptosporidium species is usually without clinical symptoms or diarrhoea. Therefore, it may be more difficult to detect C. bovis and C. ryanae from clinical samples compared with C. parvum. In addition, most studies have examined clinical samples collected from young stock because of the pathology of C. parvum. In contrast, C. bovis and C. ryanae are found mainly in older calves and stock aged 3–11 months, and the clinical samples used in this study came from animals across a wide age range. Whatever the case, our data show that this method can be used to detect the presence of CSpV1 in C. bovis and C. ryanae. Clearly, this first CSpV1 detection spurs interest in the Cryptosporidium-virus interaction, in particular, the host factors that determine or modulate CSpV1 infection. Further studies regarding the identification of animal factors and host interactions in relation to CSpV1 infection are warranted.

Our current study showed that there is no correlation between the presence of CSpV1 and the breed of calf, suggesting that Cryptosporidium is widespread regardless of host factors such as breed. Most subtyping studies have focused on the C. parvum GP60 gene; therefore, additional high-resolution tools for tracking different Cryptosporidium species and subtypes may be required. Here, sequence analysis of 25 samples using the partial dsRNA2 sequence rather than the GP60 gene sequence revealed greater genetic diversity among the virus sequences from several isolates even though the partial dsRNA2 sequence is shorter than the GP60 gene sequence. In addition, CSpV1 seems to be non-species specific based on the similarity observed among the CSpV1 sequences from samples infected with C. bovis, C. ryanae, or C. parvum. Taken together, our data show that this partial dsRNA2 sequence could be used as an alternative marker for Cryptosporidium detection and identification.

In summary, we have shown that a partial dsRNA2 sequence from CSpV1 is a useful PCR target for the detection of Cryptosporidium and CSpV1 from clinical samples without the need for purification of Cryptosporidium oocysts. This method will be of value in Cryptosporidium and CSpV1 detection and identification.

Acknowledgements

The authors would like to thank the veterinarians of the different prefectures for collecting the specimens and collaborating with us. This study was funded by grants-in-aid for Scientific Research (B:17H03913) and (C:16KT0141) and Scientific Research on Innovative Areas (3805) from the Ministry of Education, Culture, Science, Sports, and Technology (MEXT) of Japan, and by a Livestock Promotional Subsidy from the Japan Racing Association. We would like to thank the Ministry of higher Education and Scientific Research, the Arab Republic of Egypt for support during this study in accordance with the Egypt-Japan Education Partnership (EJEP).
References


Therapeutic effect of bovine amniotic fluid in murine dry eye model

Kadri Kulualp\textsuperscript{1,\,*}, Servet Kılıç\textsuperscript{2}, Yesari Eröksüz\textsuperscript{3}, Hatice Eröksüz\textsuperscript{3} and Abdullah Aslan\textsuperscript{4}

\textsuperscript{1}Department of Surgery, Faculty of Veterinary Medicine, Dokuz Eylül University, İzmir, Turkey
\textsuperscript{2}Department of Surgery, Faculty of Veterinary Medicine, Namik Kemal University, Tekirdağ, Turkey
\textsuperscript{3}Department of Pathology, Faculty of Veterinary Medicine, Firat University, Elazığ, Turkey
\textsuperscript{4}Department of Molecular Biology and Genetics, Faculty of Science, Firat University, Elazığ, Turkey

Received for publication, September 21, 2019; accepted, May 20, 2020

**Abstract**

This study investigated the therapeutic effect of bovine amniotic fluid (BAF) in dry eye (DE) model in 60 female BALB/c mice divided equally into 6 groups. Control group (CG) received 5 µL formal saline and experimental groups 0.2% benzalkonium chloride in both eyes twice a day during 14 days. From 15 to 30 days while CG and DE group only was administered saline, other groups called BAF20, BAF35, BAF50 and BAF100 received 5 µL 20, 35, 50 and 100% BAF three times a day, respectively. On day 15, in all experimental groups tear production decreased, tear break-up time shortened, corneal fluorescein staining score increased compared to baseline; on day 30, for these parameters the most effective BAF concentrations were 35%, 50% and 100%. According to western blot analysis the lowest levels were obtained in CG and BAF35 groups for tumor necrosis factor \( \alpha \) (TNF-\( \alpha \)), vascular endothelial growth factor (VEGF) and cytokeratin 10 (K10); CG for adiponectin receptor-1 (AdipoR1); BAF35 and CG for adiponectin receptor-2 (AdipoR2) \((P < 0.05)\). In the immunohistochemical analysis the lowest levels were in CG, BAF35, BAF50 and BAF100 groups for TNF-\( \alpha \), VEGF and K10; CG, BAF35 and BAF50 groups for AdipoR1; CG, BAF20, BAF35 and BAF50 groups for AdipoR2 \((P < 0.05)\). TUNEL method revealed a lower apoptotic cell score in all BAF groups \((P > 0.05)\). In conclusion; moderate to high concentrations of BAF have the more beneficial effects on DE at molecular and clinical signs and it can be used for the treatment.

**Key Words:** bovine amniotic fluid, dry eye, inflammation, mice, treatment

**Introduction**

Dry eye (DE) is a chronic multifactorial disorder induced primarily by high rate of inflammatory cytokine release as a result of tear hyperosmolarity, increased precorneal tear film (PTF) instability and hyperactivity of immune components in ocular surface cells\textsuperscript{17,57}. DE is characterized by ocular surface impairment, inflammation, precorneal tear film instability and visual disturbances\textsuperscript{49,54,57}. The current DE treatment modalities are based on increasing PTF stability, maintaining normal tear osmolarity, preventing apoptosis and inflammation and providing ocular surface homeostasis\textsuperscript{52,57}. The main purpose of DE management is to remove the underlying causes of the disease playing roles in its pathogenesis\textsuperscript{14,15} with resultants of relieved clinical symptoms and improved the patient of life quality\textsuperscript{51,57}. Recently, the therapeutic benefits of
some biological agents, similar to natural tears including autologous serum, umbilical cord serum and human amniotic membrane and fluid, on DE widely have been investigated\textsuperscript{44,45,53}. In earlier studies indicated that human amniotic membrane and fluid contain high amounts of growth factors vital for fetal development and revealed to induce corneal sensitivity, promote nerve regeneration and decrease epithelial damage as well as scar tissue formation in alkali burn cornea\textsuperscript{18,26}. It has also been reported that these agents contain hyaluronic acid which is an anti-inflammatory polysaccharide\textsuperscript{11,43,48}. In a mouse DE model study\textsuperscript{44} in which the therapeutic effects of some body fluids and tear preparations were compared, it was found that human amniotic fluid yielded better results in terms of corneal fluorescein staining and goblet cell density than artificial tear preparations and human serum. Another study reported\textsuperscript{45} that higher concentration of human amniotic fluid has better therapeutic effects on DE than its lower concentrations. Bovine has a well-developed allantoic cavity and a large amount of amniotic fluid. Bovine amniotic fluid (BAF), which is rich in proteins, minerals and cells, has the advantages of being inexpensive and easy to obtain\textsuperscript{12}. In a study on acute corneal alkali burns of rat, BAF was found to reduce corneal erosions, edema and keratinization. These results indicate that BAF may be an alternative therapeutic agent in veterinary ophthalmology\textsuperscript{16}. To our knowledge, up to now no study has investigated the therapeutic benefits of BAF on DE.

DE models can be established utilizing aquaternary ammonium compound, benzalkonium chloride (BEC), an active ingredient of ophthalmic preparations with antimicrobial action\textsuperscript{36,56}. BEC rapidly induces DE via disrupting the lipid phase of PTF and disintegrating corneal epithelial cell membrane\textsuperscript{36}.

The aim of this study was to investigate the therapeutic effects of 4 different concentrations of BAF, a biological fluid, in murine DE model induced with BEC.

Materials and Methods

**Experimental procedure:** This study was conducted in accordance with the Association for Research in Vision and Ophthalmology (ARVO) Statement for the Use of Animals in Ophthalmic and Vision Research, and it was approved by the Firat University Animal Experiments Local Ethics Committee (2016/4/34). The material in the study consisted of 60 BALB/c female mice with average weights of 18–20 g and average ages of 6–8 weeks. During the study, the subjects were kept in a room with an ambient temperature of 24°C ± 1°C, relative humidity of 60% ± 10%, and a light-dark cycle of 12 hours. No food and water restrictions were applied during the study. Following clinical and ophthalmological examinations, the subjects that were determined to be healthy were included in the study. One week prior to the experiment, all the subjects were transferred to an independent room, where they were kept in conventional mouse cages. Experimental procedures were performed using a funnel shaped hard plastic restraint\textsuperscript{22}, the narrower end of which had a hole large enough for a mouse to pass its head through. To obtain the measurements, the animals were encouraged to pass through the restraint several times. Then, they were randomly divided into 6 groups (n=10 x 6). Group I served as the control group (CG); the other 5 groups (1 experimental group, the dry eye [DE] group and 4 BAF treatment groups) were topically administered 5 μL of 0.2% BEC in both eyes twice a day (09:00, 21:00) for 14 days to induce the DE model. During this time, the CG subjects received the same amount of saline and the same time points\textsuperscript{55}. The subjects in the CG and DE groups (Group II) received 0.9% saline 3 times a day (09:00, 15:00, and 21:00) for a 15-day therapeutic period; the subjects in the other 4 groups (BAF treatment groups) were administered 20% BAF (Group III, BAF20), 35% BAF (Group IV, BAF35), 50% BAF (Group V, BAF50), and 100% BAF (Group VI, BAF100) at the same intervals and the same time points. At the end of the study, the mice were
decapitated, and the eye tissues were carefully collected and stored at -80°C until the Western blot (WBlot), immunohistochemical (IHC), and terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) analyses were conducted.

**Procurement and Preparation of BAF**: BAF was obtained from a 270±2 day pregnant cow that had a prolapsed vagina and a closed cervix uterus. The fluid was collected during the caesarean section procedure under sterile conditions, centrifuged at 3,000 rpm for 15 min and stored at -20°C until used. During use, it was kept at 4°C to prevent bacterial contamination. The BAF in Group III, Group IV, and Group V was diluted at concentrations of 20% (BAF20), 35% (BAF35), and 50% (BAF50), respectively, with isotonic saline; the BAF in Group VI (BAF100) was pure or used without dilution solution.

**Procedure of the clinical parametric tests**: In all the groups, the tear production rate, tear break-up time (TBUT), and corneal fluorescein staining tests were measured 7 times; baseline (before the experiment) and after inducing the DE model on days 15, 18, 22, 25, 28, and 30 at the same time points (13:00–15:00). During each measurement, any ocular abnormalities (photophobia, ocular discharge and redness, conjunctivitis, keratitis) were also noted.

**Measurement of tear production rate with Endodontic Absorbent Paper Point Test (EAPPTT)**: As test material Roeko Color (Color size 30, Langenau, Germany) brand, a gold standard for this particular measurement was used. After ensuring the physical restraint, the test strips were placed in the lower conjunctival fornix near the lateral canthus of each eye and left in place for 1 min. Measurement was performed in both eyes simultaneously. After the test strips were removed, the length of wetness on the strips was read on an millimeter scale and average data of both eyes were recorded.

**TBUT**: With a micro-injector (901 N, Hamilton, USA) 1 μL 0.1% liquid sodium fluorescein (Fertility Chemical Laboratory, Istanbul, Turkey) was instilled into the left and right eyes of each subject. After 3 blinks, the eye lids were withheld with fingers and under the slit-lamp biomicroscope (XL-1, Shin-Nippon, Osaka, Japan) the moment the tear break up occurred the first was noted and the average value of the both eyes was recorded.

**Corneal fluorescein staining test**: In all the experimental subjects, 90 sec after the TBUT, the corneal staining rate was assessed using the slit-lamp biomicroscope with a cobalt blue filter; and the detected corneal lesions were photographed under an operation microscope. The lesions were scored as 0: no staining on the corneal surface; 1: a staining area equal to or less than 1/8; 2: a staining area equal to or less than 1/4; 3: a staining area equal to or less than 1/2; and 4: a staining area more than 1/2 or covering the entire corneal surface.

**Total protein isolation**: Corneocconjunctival tissue samples (Half of each group; 5 samples of both eyes) were washed with cold phosphate buffered saline (PBS) and protein isolation was performed with UPX Universal Protein Extraction Kit (Expedeon, UK), after protein isolation, the protein samples were kept at -20 °C until analysis.

**Analysis of VEGF, TNF-α, K10, adiponectin receptor 1 (AdipoR1), and adiponectin receptor 2 (AdipoR2) protein expression levels using the WBlot technique**: First, the protein concentrations of corneoconjunctival tissue were measured with a Lowry kit. About 30 μg of the protein samples was loaded into each wells of Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis (SDS-PAGE), later, the protein samples of the corneoconjunctival tissue were run on 12% gel via the SDS-PAGE and carried to a nitrocellulose membrane. The samples were then incubated overnight at 4 °C with primary antibodies against VEGF (sc-7269, Santa Cruz-Germany), TNF-α (ab8348, Abcam-UK), K10 (NB1-97795, Novus Bio-USA), AdipoR1 (ab126611, Abcam-U.K.), AdipoR2 (ab77612, Abcam-U.K.), and beta-actin (sc-47778, Santa Cruz-Germany) (dilution: 1/500 for all antibodies).
After, the protein samples were incubated by the HRP-conjugated secondary antibody (1/1000) for 60 min at room temperature, the nitrocellulose membrane was colored with DAB and the protein levels calculated with an image program (Image J; National Institutes of Health, Bethesda, MD, USA)³,²,⁸.

**Tissue fixation and processing:** After the mice were decapitated, their left and right eyes were removed for WBlot and IHC, fixed in 10% neutral buffered formaldehyde, sectioned in the vertical plane adjacent to the optic nerve, and embedded in paraffin. Serial sections in 5 μm thickness including the cornea, retina and optic nerve were cut.

**IHC analysis:** The paraffin embedded sections were deparaffinized in xylene and dehydrated using a series of graded alcohol. UltraVision™ ONE Detection System: HRP Polymer/ AEC Chromogen (ThermoFisher Scientific, Rockford, IL, USA) was used according to the manufacturer’s protocol. Briefly; antigen retrieval was accomplished by microwaving the sections for 15 min in Citrate Buffer at pH6, then allowed to cool for 20 min. The sections were washed in PBS and primary antibodies were applied after Hydrogen Peroxide Block (5 min) and Ultra-V Block (5 min). The sections were incubated in primary antibodies, including VEGF (1/100, sc-7269), TNF-α (1/100, ab8348), K10 (1/100, NBP1-97795), AdipoR1 (1:20, ab126611), AdipoR2 (1:250, ab77612). Then incubation with primary antibodies against immunodetection was performed for 60 min at 37 °C with biotinylated goat anti–polyvalent, followed by peroxidase-labeled streptavidin using a labeled streptavidin biotin kit with a 3- Amino-9-Ethylcarbazol(AEC) (ThermoFisher Scientific, Rockford, IL, USA), as the chromogen substrate. The sections were counterstained with Gill’s hematoxylin, and coverslips were attached using aqueous mounting media. The intensity and prevalence of the IHC staining was scored on a scale of 0 to +3 (0: absent, +1: weak, +2: medium, +3: strong). Scoring was done for each mouse, individually.

**The TUNEL method:** Sections were stained using In-Situ Cell Death Detection POD apoptosis kit (Boehringer Mannheim, Mannheim, Germany) following recommended standard procedures. After the tissue sections were taken on positively charged slides at a thickness of 5 μm, they were left to dry overnight in a 60 °C oven, deparaffinized in xylol, and dehydrated in serial alcohols. After the contours of the sections were drawn with a bounding pencil, they were kept with a 1:500 dilution of Protease K solution for 7 min at room temperature. To stop endogenous peroxidase activity, 5 min of a blockage in 3% H₂O₂ prepared in methanol was applied. Then, each section was washed with 13 μL/cm² of equilibration buffer solution for 6 min at room temperature and covered with a plastic coverslip, then left in 100 μL terminal deoxynucleotidyl transferase (TdT) enzyme solution at 37 °C for 1 hour before being transferred to protein blocking serum for 10 min to prevent non-antigenic binding. All the tissue sections were incubated with anti-digoxigenin conjugate for 30 min at room temperature. They were washed 3 times with PBS for 5 min after each procedure, except for the incubation step with the protein blocking serum. DAB was used as the chromogen. For contrast staining, Gill’s hematoxylin was used. Finally, the slides were covered with water-based adhesive (Bio-Optica, Milan, Italy). TUNEL staining was scored using the same scoring that was used in the IHC method described earlier.

**Statistical analysis:** SPSS 13.0 (SPSS Inc., Chicago, IL, USA) version was used for the statistical analysis of clinical parametric tests. An independent statistical analysis was applied to each test. Friedman test, used for non-parametric and repeated measurements, was applied to determine the difference between the different measurement times of a group for a specific test. In a group with significant differences, the Wilcoxon test was used to determine if there was a difference between the measurement times. The difference between the groups at each measurement time was assessed using Tukey’s
test in one-way analysis of variance (ANOVA). Statistical results, set to \( P < 0.05 \) or \( P < 0.001 \), were accepted as significant.

The IBM SPSS Statistics 20.0 package program was used for statistical analysis of the WBlot, IHC, and TUNEL techniques. Group variability was tested with one-way ANOVA; post-hoc, Duncan, and Games-Howell tests were used for WBlot analysis; Tukey's test was used for the IHC and TUNEL analyses. Statistical results were accepted as significant at \( P < 0.05 \). For the reliability of the statistics, the measurements were repeated at least 3 times in the WBlot analysis.

**Results**

**EAPPTT**: For the EAPPTT parameter, the difference between all the groups was significant at all the measurement times (\( P < 0.001 \); Table 1) except at baseline (\( P > 0.05 \); Table 1). On the 15\(^{th} \) day, the first measurement after BEC application, the highest aqueous tear production rate was recorded in CG, and the difference between this group and all the other groups was significant (\( P < 0.05 \); Table 1); however, the differences in the EAPPTT results between all the groups, except the CG, were insignificant (\( P > 0.05 \); Table 1). At the last measurement time of the study (30\(^{th} \) day), the mean tear production rate in the treatment groups, ranging from highest to lowest, were: BAF35, BAF50, BAF100, and BAF20, although the difference was not statistically significant (\( P > 0.05 \); Table 1).

**TBUT**: For all measurement times, except baseline the difference between groups was statistically significant (\( P < 0.001 \); Table 2). On the 15\(^{th} \) day, the highest mean TBUT mean (6.99±0.48 sec) was recorded in the CG subjects and the lowest TBUT was recorded in the DE group. The differences between all the groups on the 30\(^{th} \) day, the last measurement time of the study, were found to be statistically significant (\( P < 0.05 \); Table 2). Among the treatment groups, it was determined that the BAF50 group had longest TBUT values and the BAF20 group had the shortest TBUT values.

**Corneal fluorescein staining test**: The baseline score for all the groups was 0 (\( P > 0.05 \); Table 3). For the other measurement times, a significant difference (\( P < 0.001 \); Table 3) was observed between the groups. On the 15\(^{th} \) day of measurements, the difference between all the groups, except CG, was statistically insignificant (\( P > 0.05 \); Table 3). In the last measurement time (the 30\(^{th} \) day), the lowest mean scores among the treatment groups were recorded in BAF35, BAF50, and BAF100 groups, with no statistically significant difference between them (\( P > 0.05 \); Table 3). On the 30\(^{th} \) day, the highest mean score among these groups was recorded in the BAF20 group.

**WBlot analysis**: VEGF and TNF-\( \alpha \) inflammatory cytokine expression levels were measured in the highest DE group and the lowest in the CG and BAF35 groups, and these groups showed the significant differences with the other groups (\( P < 0.05 \); Fig. 1A,B,C). For K10, the highest levels were found in the DE, BAF20 and BAF100 groups (\( P < 0.05 \)), and the lowest levels in the CG and BAF35 groups (\( P < 0.05 \); 1A,D). AdipoR1 and AdipoR2 protein expression levels determined higher in DE group in comparison to all the other groups (\( P < 0.05 \); Fig. 1A,E,F). Compared to all other groups, the lowest AdipoR1 expression levels are in the CG group; the lowest AdipoR2 levels were measured in CG and BAF35 groups (\( P < 0.05 \); Fig. 1A,E,F).

**IHC analysis and TUNEL method**: For VEGF, it was found that immunoreactivity was evident in the corneal epithelium of the DE group (Fig. 2Aa). It was found that immunoreactivity was low in BAF50 and BAF100 groups along with BAF35 (Fig. 2Ab) in treatment groups, but not in CG (Fig. 2Ac). Immunoreactivity for TNF-\( \alpha \) was found to be evident in the corneal epithelium and subepithelial corneal stromal cells of the DE group (Fig. 2Ba). In the treatment groups, immunoreactivity was lower in BAF35 (Fig. 2Bb).
Table 1. Statistical analysis of EAPPTT data according to measurement times and group variables (Mean ± standard deviation). *Baseline values of the study, a-f: There is a significant difference between groups containing different letters on the same line. (P < 0.05), ANOVA-Posthoc, Tukey test were used. A-F: The differences between groups that contain different letters on the same line are significant. (P < 0.05). Friedman was used for non-parametric tests and Wilcoxon test for intra-group comparisons. (n=10x6 group)

<table>
<thead>
<tr>
<th>Groups</th>
<th>Measurement Times</th>
<th>...P...</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Baseline*</td>
<td>15th day</td>
</tr>
<tr>
<td>CG</td>
<td>4.5±0.32</td>
<td>4.74±0.37</td>
</tr>
<tr>
<td>DE</td>
<td>4.79±0.41</td>
<td>2.47±0.23</td>
</tr>
<tr>
<td>RAF20</td>
<td>4.50±0.36</td>
<td>2.39±0.27</td>
</tr>
<tr>
<td>RAF35</td>
<td>4.60±0.29</td>
<td>2.47±0.20</td>
</tr>
<tr>
<td>RAF50</td>
<td>4.59±0.31</td>
<td>2.42±0.28</td>
</tr>
<tr>
<td>RAF100</td>
<td>4.44±0.29</td>
<td>2.43±0.19</td>
</tr>
</tbody>
</table>

Table 2. Statistical analysis of TIBUT data according to measurement times and group variables (Mean ± standard deviation). *Baseline values of the study, a-f: There is a significant difference between groups containing different letters in the same column. (P < 0.05), ANOVA-Posthoc, Tukey test were used. A-F: The differences between groups that contain different letters on the same line are significant. (P < 0.05). Friedman was used for non-parametric tests and Wilcoxon test for intra-group comparisons. (n=10x6 group)

<table>
<thead>
<tr>
<th>Groups</th>
<th>Measurement Times</th>
<th>...P...</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Baseline*</td>
<td>15th day</td>
</tr>
<tr>
<td>CG</td>
<td>7.25±0.44</td>
<td>6.98±0.48</td>
</tr>
<tr>
<td>DE</td>
<td>6.99±0.33</td>
<td>2.14±0.32</td>
</tr>
<tr>
<td>RAF20</td>
<td>7.37±0.25</td>
<td>2.46±0.39</td>
</tr>
<tr>
<td>RAF35</td>
<td>7.19±0.21</td>
<td>2.69±0.21</td>
</tr>
<tr>
<td>RAF50</td>
<td>7.27±0.41</td>
<td>2.17±0.29</td>
</tr>
<tr>
<td>RAF100</td>
<td>7.30±0.38</td>
<td>2.62±0.27</td>
</tr>
</tbody>
</table>

Table 3. Statistical analysis of corneal fluorescein staining test scores according to measurement times and group variables (Mean ± standard deviation). *Baseline values of the study, a-d: There is a significant difference between groups containing different letters in the same column. (P < 0.05), ANOVA-Posthoc, Tukey test were used. A-G: The differences between groups that contain different letters on the same line are significant. (P < 0.05). Friedman was used for non-parametric tests and Wilcoxon test for intra-group comparisons. (n=10x6 group)

<table>
<thead>
<tr>
<th>Groups</th>
<th>Measurement Times</th>
<th>...P...</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Baseline*</td>
<td>15th day</td>
</tr>
<tr>
<td>CG</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>DE</td>
<td>0*</td>
<td>3.55±0.37</td>
</tr>
<tr>
<td>RAF20</td>
<td>0*</td>
<td>3.65±0.34</td>
</tr>
<tr>
<td>RAF35</td>
<td>0*</td>
<td>3.69±0.39</td>
</tr>
<tr>
<td>RAF50</td>
<td>0*</td>
<td>3.61±0.32</td>
</tr>
<tr>
<td>RAF100</td>
<td>0*</td>
<td>3.39±0.39</td>
</tr>
</tbody>
</table>
2Bb) and BAF50 and BAF100. In CG, there was no immunoreactivity (Fig. 2Bc). For K10, immunoreactivity was most prominently detected in the corneal epithelium of the DE group (Fig. 2Ca). Immunoreactivity was found to be less pronounced in BAF50 (Fig. 2Cb) and BAF35 and BAF100. In CG, there was no immunoreactivity (Fig. 2Cc). Immunoreactivity for AdipoR1 was evident detected in the corneal epithelium of the DE group (Fig. 2Da). Immunoreactivity was less pronounced in the BAF50 group with BAF35 (Fig. 2Db). There was no AdipoR1 immunoreactivity in CG (Fig. 2De). Immunoreactivity for AdipoR2 was evident in the corneal epithelium of the DE group (Fig. 2Ea). It was found less in BAF20 and BAF35 groups with BAF50 (Fig. 2Eb). There was no AdipoR2 immunoreactivity in CG (Fig. 2Ec). In TUNEL staining, the number of apoptotic cells in the corneal epithelium of the DE group was found to be high (Fig. 2Fa). While the number of apoptotic cells was less common in BAF50 (Fig. 2Fb) and other treatment groups, it was not detected in CG (Fig. 2Fc). When all groups were evaluated according to the severity scores of the immunoreactive cells; for VEGF, the immunoreactive cell score was measured at the highest DE ($P < 0.05$) and the lowest at CG($P < 0.05$). In the treatment groups, the severity score of all the groups except for BAF20 was low (Fig. 3A). For TNF-α K10, the immunoreactive cell score was highest in the DE group($P < 0.05$) and the lowest in all other groups except BAF20 (Fig. 3B,C). For AdipoR1, the immunoreactive cell score was highest in the DE group ($P < 0.05$) and lowest in the CG, BAF35 and BAF50 groups (Fig. 3D). For AdipoR2, the immunoreactive cell score was highest in the DE group ($P < 0.05$) and lowest in all other groups except BAF100 (Fig. 3E). For TUNEL, the immunoreactive cell score was highest in the DE group ($P < 0.05$), lowest in the CG group ($P < 0.05$), and low in all treatment groups with no statistically significant difference ($P > 0.05$) between them (Fig. 3F).

**Discussion**

DE is an complex ocular disorder characterized by excessive evaporation of the aqueous and alteration of the mucin components of PTF due to increased tear osmolarity, corneal and conjunctival epithelial damage, squamous metaplasia, and dysfunction or inflammation of the ocular surface and the tear glands$^{19,52,55,57}$. To date, many experimental DE models have been established to investigate its complex pathogenesis and realize novel and effective treatment options$^{1,4,5,8,10,21,37,50}$. Xiong et al$^{56}$ suggested that, although these models provide important data about the disease, each of them has its own characteristics and limitations; therefore, they do not fully reflect the complex etiopathogenesis and chronic form of DE. In their DE rabbit model, these investigators used BEC, a preservative constituent of ophthalmic preparations, as the DE inductive agent, which is well-known to rapidly and progressively destabilize PTF via altering its lipid and mucin layers. They found that BEC can reduce the amount of aqueous tear production and conjunctival goblet cells and increase corneal fluorescein and Rose Bengal staining areas in subjects. Many in vivo studies performed using mice$^{24,36}$, rats$^{41}$, cats$^{6}$ and rabbits$^{56}$ have shown that BEC also induces corneal and conjunctival inflammatory cell infiltration, excessive release of pre-inflammatory mediators, PGF instability, conjunctival goblet cell loss, corneal epithelial desquamation, erosions, ulceration, and corneal neovascularization. Considering its negative effects on the ocular surface, many researchers$^{19,36,55,56,59}$ have recently used BEC to establish a successful DE model in different animal species. The present study established murine DE model by topically applying 5 μL 0.2% BEC to both eyes of the subjects for 14 days. At the end of this period, the average tear production rate decreased, the TBUT shortened and corneal fluorescein staining scores increased significantly in comparison to the baseline values.
in all subjects except for those in the CG having no BEC. It was also observed that all these abnormalities continued in the DE group until the end of the study. According to WBlot and IHC analyses of the corneal and conjunctival tissues obtained from all the group subjects at the end of the study, the levels of inflammatory cytokines, such as TNF-α and VEGF, and K10, markers of squamous metaplasia, and levels of AdipoR1 and AdipoR2, indicators of inflammatory responses, were significantly different among the groups. This indicates that bovine amniotic fluid may have therapeutic potential in treating dry eye disease.
reaction, increased in the DE group. When all these parameters are evaluated together, it was concluded that BEC produced an effect similar to DE in both the molecular and clinical levels.

A decrease in the aqueous tear production rate, the most prominent clinical symptom of DE, triggers many inflammatory eye diseases, including DE, by activating the inflammatory process. In recent years, EAPPTT has been used to measure the amount of aqueous tear...
production in experimental studies using small laboratory and exotic animals\textsuperscript{29,30}. This test was also used in the present study. Mean EAPPTT recorded in the initial measurements (baseline) of all subjects showed a statistically significant decrease tear rate in all the experimental groups in comparison to the tear rate at the time (14 days) of the first measurement after BEC administration. These data show that BEC causes a significant reduction in aqueous tear production. This reducing trend, which continued until the end of the study, especially in DE group, indicates that BEC suppresses the amount of aqueous tear production as long as it is applied. In murine DE models, where DE was induced twice daily with 0.2\% BEC for 14 days\textsuperscript{59} and with 0.1\% BEC for 10 days\textsuperscript{55}, and where phenol red cotton thread test (PRTT) was used to measure aqueous tear production, this agent was found to significantly reduce aqueous tear production. Similar results
Kadri KULUALP et al.

have been obtained in other DE model studies using BEC23,36,54. In the present study, when the treatment groups were evaluated according to the aqueous tear production parameter, it was found that the mean EAPPTT increased continuously for all the groups, except for the BAF20 group, at all measurement times after 15 days, and the difference between these groups at the last measurement (30th day) was not statistically significant. In a DE model investigating the therapeutic effects of 3 different concentrations of human amniotic fluid (20%, 50% and 100%), it was reported that all concentrations significantly increased aqueous tear production within 2 weeks; however the best result was obtained in amniotic fluid concentrations of 50% and 100%. A similar result was obtained in another study using pure HAF; that study reported that pure HAF significantly decreased the corneal fluorescein score44. In the present study, as in the HAF study, the moderate and high concentrations of BAF (35%, 50%, and 100%) were found to have the most beneficial effect on the amount of aqueous tear production.

Evaluation of PTF stability is important, especially in revealing mucin and lipid tear deficiencies and determining dysfunction of meibomian gland47,52. In many DE model studies11,19,32,36,51,54,55,59 tear film stability has been evaluated using TBUT. In a DE model in which 0.2% BEC was administered topically for 7 days in mouse eyes, it was found that TBUT gradually decreased in the experimental group in comparison to the CG, and the difference between these two groups was statistically significant59. Similar results were obtained in other DE model studies where 0.1% BEC was applied topically for 10 days55 and 0.2% BEC for 14 days59. In the present study, mean TBUT was recorded as 7.00–7.37 sec in the baseline measurement in all the subjects, which decreased to 2.15–2.69 sec at the first measurement time after 14 days of BEC application. These data show that BEC impairs PTF stability in subjects. Mean TBUT measured on day 15 in all treatment groups was observed to be almost twice as long on day 30, the last measurement time of the study. Xiao et al.55 found that the human amniotic membrane prolongs TBUT in aBEC induced DE model. Our study found beneficial effect on TBUT in all groups, with the longest TBUT value in the BAF50 group.

The corneal fluorescein staining test is routinely used to determine epithelial damage, PGF quality and ocular surface abnormalities39. Many DE studies on animals have reported that DE causes tear film instability, ocular inflammation, conjunctival goblet cell loss, and corneal neovascularization as well as corneal epithelial cell shedding and corneal erosions and ulceration19,36,56,59. Xiao et al.44 determined that the corneal fluorescein staining scores increased in the first measurements of the subjects received 0.2% BEC twice a day for 14 days, the scores gradually started to decrease after BEC administration was discontinued. Using the same model, our study found that the corneal fluorescein staining score significantly increased in all the experimental groups at the first measurement time after administering BEC for 14 days in comparison to the baseline measurement. After stopping the BEC application and starting the BAF treatment, the corneal fluorescein staining scores decreased continuously until the end of the study in all treatment groups except for the BAF20 group. In the terms of the last measurement, the difference in the corneal fluorescein staining scores between the BAF35, BAF50, and BAF100 groups was not significant. Similar to our results, Quinto et al.55 found that moderate and high density human amniotic fluid reduced the corneal fluorescein staining scores more effectively than a20% of BAF.

Ocular surface inflammation plays a key role both as a cause and a result of the pathogenesis of the DE cycle36,59. Experimental studies have revealed inflammatory cell infiltrations and increased levels of inflammatory cytokine and chemokine (IL-1α-β, TNF-α, VEGF) in the lacrimal tissues and ocular surface epithelium of DE
EFFECTS OF BOVINE AMNIOTIC FLUID IN DRY EYE patients. Recently, many researchers who recognized the importance of the inflammatory process on DE pathogenesis have focused on measuring the levels of inflammatory cytokines and chemokine in the ocular tissues of the subjects using different techniques. In the present study, the WBlot and IHC analyses showed that the DE group had the highest VEGF and TNF-α levels, suggesting that BEC induces an inflammatory reaction in corneoconjunctival tissues. As a matter of fact, the lowest VEGF and TNF-α levels in the treatment groups were recorded in the BAF35 group in the WBlot analysis and in the BAF55, BAF50, and BAF100 groups in the IHC analysis. These data from the treatment groups indicate that moderate and high concentrations of BAF have a positive effect on the inflammatory process of DE. It has also been suggested that this increase in the concentrations of the cytokines may accelerate the development of squamous metaplasia via inflammatory reaction. Squamous metaplasia, conversion of corneal epithelial cells to keratinizing cells or non-keratinized epithelium into squamous epithelium, is considered to be one of the important symptoms of chronic inflammatory diseases, such as DE. The presence of squamous metaplasia is demonstrated by increases in the level of K10, an epidermis-specific cytokeratin. Recent DE model studies using different measurement techniques showed that the K10 levels were significantly higher in the corneal epithelium of the DE groups comparison to the controls. In the present study, the highest K10 levels in the corneoconjunctival tissue were recorded in DE, BAF20, and BAF100 groups using the WBlot technique and in the DE and BAF20 groups using IHC staining. As reported in previous studies, the results indicate that BEC-induced DE causes squamous metaplasia in the corneal epithelium of the subjects. In the present study, the lowest K10 levels were measured in the CG and the BAF35 groups according to WBlot analysis and in the BAF35, BAF50, and BAF100 groups according to IHC analysis. When the results of both analyses was evaluated together, the K10 levels were found to decrease significantly in all the treatment groups, except the BAF20 group.

Adiponectin, a protein that secrets from adipose tissues and is abundant in plasma, has anti-inflammatory, anti-diabetic, and anti-angiogenic properties in different tissues. From this protein, three different receptors have been identified: AdipoR1, AdipoR2, and T-cadherin. Katsiougiannis et al. reported that inflammation accelerates adipose and fibrotic tissue formation in the lacrimal glands and ocular tissue; and this suggests that adipocytes may be an important marker in the defense or repair repertoire of these tissues. In the present study, the WBlot and IHC analyses showed that the DE group had the highest AdipoR1 and AdipoR2 levels, which supports the claims of Katsiougiannis et al. that adipocyte density increased in cases of inflammation. When the WBlot and IHC analyses were evaluated together, the AdipoR1 and AdipoR2 levels were lower in the BAF treatment groups than the DE group. These results indicate that BEC has an inflammatory effect on the ocular surface and that different concentrations of BAF suppress this inflammatory process to varying degrees.

It is suggested that the inflammatory process that plays a key role in DE pathogenesis and the subsequently development of squamous metaplasia induces epithelial apoptosis. Apoptosis positive cells have been reported in the cornea, the conjunctiva, and the lacrimal glands using the TUNEL method. Some studies have reported that a high concentration of preservative agents, such as BEC, cause necrosis while low concentrations cause apoptosis. In the present study, in all groups, a positive staining response was obtained in the epithelial and stromal layers of the cornea with the highest apoptotic cell score in the DE group and the lowest score in CG; no significant difference in the apoptotic cell score was found between the treatment groups. Moreover, the apoptotic cell
score was lower in the BAF treatment groups than the DE group. Similar results have also been reported in previous studies\(^1,36,55\), which found that low BEC concentrations may lead to epithelial apoptosis on the ocular surface. Furthermore, the efficacy of all the BAF concentrations against epithelial apoptosis in which we compared the therapeutic effects supports the view expressed Lin et al.\(^36\) that suppression of apoptosis is important in the treatment of ocular surface disorders.

In the present study, all the parameters, including the clinical tests and observations as well as the WBlot, IHC, and TUNEL analyses, demonstrate that moderate to high concentrations of BAF had positive effects on both the molecular and clinical signs of BEC-induced DE. The diagnostic methods used in this study were designed by considering the relationship between the clinical forms of DE and pathogenesis this condition. In two previous DE models\(^44,45\) in which the therapeutic effect of HAF was investigated, the diagnosis was largely established based on the results of clinical tests; however, in addition to these tests, the present study used specific complementary molecular tests, such as IHC, WBlot, and TUNEL, to implement an inclusive diagnostic strategy to investigate the therapeutic effect of BAF, expecting it to be an alternative biological agent to HAF. This approach allowed the results obtained from each measurement technique to be interrelated and supportive, thus enabling a broader evaluation of the study.

**Acknowledgements**

This study was financially supported by The Scientific and Technological Research Council of Turkey (TUBITAK). (Project number: 116O927). The data of this study were presented as an oral presentation at the 24th International Veterinary Surgery Congress of Turkey.

**References**

3) Aslan A. The effects of different essential fruit juice and their combination on Saccharomyces cerevisiae cell growth. Prog Nutr 17, 36-40, 2015.


48) She Y, Li J, Xiao B, Lu H, Liu H, Simmons PA, Vehige JG, Chen W. Evaluation of a Novel Artificial Tear in the Prevention and


Cold Exposure Increases Circulating miR-122 Levels via UCP1-Dependent Mechanism in Mice

Jussiaea Valente Bariuan¹, Yuko Okamatsu-Ogura¹, Ayumi Tsubota¹, Shinya Matsuoka¹, Masayuki Saito¹ and Kazuhiro Kimura¹

¹Laboratory of Biochemistry, Faculty of Veterinary Medicine, Hokkaido University, Sapporo 060-0818, Japan

Received for publication, February 27, 2020; accepted, May 21, 2020

Abstract

MicroRNA(miR)-122 is highly expressed in liver and secreted into blood, which is reported to enter other tissues to modulate lipid metabolism. Brown adipose tissue (BAT) is responsible for non-shivering thermogenesis required for body temperature maintenance in cold environments. Since BAT activity is deeply related to lipid metabolism, there may be metabolic crosstalk between the liver and BAT through miR-122. In this study, we examined the effect of cold exposure on circulating miR-122 (cir-miR-122) levels in mice. Cold exposure significantly increased the expressions of Uncoupling protein 1 (Ucp1), a key molecule for thermogenesis, indicating the activation of BAT. Cold exposure significantly increased cir-miR-122 level but caused no change in miR-122 and its precursor levels in the liver. In contrast, cold exposure significantly decreased miR-122 level in the muscle, but not in BAT, suggesting that increased cir-miR-122 was due to the enhancement of its secretion from the muscle. To examine whether BAT thermogenesis was a prerequisite for increased cir-miR-122 and decreased miR-122 level in the muscle, effect of cold exposure was examined in UCP1-KO mice. While the expressions of thermogenesis-related genes in BAT, except for that of Ucp1, was increased after cold exposure, no significant changes were observed in cir-miR-122 and muscle miR-122 level in UCP1-KO mice. These results suggest that cold-induced activation of BAT thermogenesis increased cir-miR-122 through the secretion from muscle, although further study is required to find the missing link between BAT thermogenesis and miRNA secretion from the muscle.

Key Words: brown adipose tissue, cold exposure, miRNA, skeletal muscle, uncoupling protein 1

Introduction

Mammals have two types of adipose tissue⁸,¹². White adipose tissue (WAT) stores energy as triglyceride and releases fatty acids when required. Brown adipose tissue (BAT) is a specialized tissue for non-shivering thermogenesis which depends on uncoupling protein 1 (UCP1), a mitochondrial protein specifically expressed in brown adipocytes. BAT thermogenesis plays an important role in the regulation of body temperature especially in a cold environment. Cold stimulation activates sympathetic nervous system (SNS), and norepinephrine (NE) released from nerve endings activates the ß-adrenergic receptor (ß-AR), particularly ß3-AR which is predominantly expressed in adipocytes, and induces lipolysis in both white and brown adipocytes. In brown adipocytes, liberated fatty acids (FAs) activate thermogenic activity of
UCP1 and are simultaneously used as substrates for thermogenesis \(^{(17)}\). FAs released from white adipocytes are also used in brown adipocytes for thermogenesis \(^{(9)}\). The indispensable role of BAT-UCP1 thermogenesis in the regulation of body temperature is evidenced by the fact that the mice deficient in UCP1 are unable to maintain body temperature in a cold environment \(^{(15)}\).

MicroRNAs (miRNAs) are short, endogenous non-coding RNAs that inhibit gene expression by targeting mRNAs for translational repression or cleavage \(^{(22,26)}\). Several miRNA have been reported to regulate brown adipogenesis \(^{(24,28,31)}\). miRNAs exist not only inside of cells but also in a variety of body fluids by binding to lipids or proteins or being packed in exosome, a small extracellular vesicle stably existing in fluid \(^{(19,22)}\). miRNA transported to other cells, can exhibit their effects in a paracrine and endocrine-like manner \(^{(13,32)}\). Brown adipocytes are reported to secrete miR-92a, and the serum level of exosomal miR-92a is correlated with BAT activity in both humans and mice \(^{(10)}\).

miR-122 is miRNA expressed abundantly in liver that are found in high levels in the circulation. As such, circulating miR-122 is used as a biomarker for variety of liver pathologic conditions \(^{(4)}\). Intracellular miR-122 plays a pivotal role in regulation of lipid metabolism through the direct targeting of the genes involved in triglyceride (TG) synthesis, such as Agpat1 \(^{(21)}\) and Dgat1 \(^{(9)}\), or the indirect unknown mechanism. Liver-specific knockout of miR-122 mice shows TG accumulation in liver, due to the enhancement of TG synthesis and decreased secretion \(^{(21)}\). On the other hand, expression and secretion of hepatic miR-122 is regulated by FAs. Chai et al., revealed that injection of β3-AR agonist activated lipolysis in WAT, and mobilized FAs to act on liver to increase the expression and secretion of miR-122 \(^{(9)}\). Thus, it is likely that adipose tissue is involved in the regulation of circulating miR-122 level through FAs. Although β3-AR agonist simultaneously induces BAT thermogenesis, the role of BAT in miR-122 metabolism has not been examined. It was also shown that the circulating miR-122 entered other tissues including muscle, and reduced triglyceride storage by targeting mRNAs of enzymes involved in the triglyceride synthesis \(^{(9)}\).

As mentioned above, BAT uses fatty acids for thermogenesis. It is also reported that BAT activation resulted in the clearance of plasma triglyceride and cholesterol \(^{(5-7)}\). Since the BAT activity is deeply related with lipid metabolism, it is possible that there is metabolic organ crosstalk between the liver and BAT through miR-122. In this study we analyzed circulating miR-122 in mice with activation of BAT thermogenesis by cold exposure.

**Materials and Methods**

**Animals**

The experimental procedures and care of animals were approved by the Animal Care and Use Committee of Hokkaido University. All experiments using mice were conducted in an animal facility approved by the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC) International. UCP1-KO (Ucp1\(^{-/-}\)) mice were kindly provided by Dr. L. Kozak (Pennington Biomedical Research Center, Baton Rouge, LA, U.S.A). All wild-type (WT; Ucp1\(^{+/+}\)) mice were C57BL/6J strain. Male C57BL/6J mice were purchased from Japan SLC Inc. (Hamamatsu, Japan). Mice were bred and housed in plastic cages placed in a room temperature controlled to 23±2°C with a 12:12 hr light: dark cycle and given free access to laboratory chow (Oriental Yeast, Tokyo, Japan).

Mice of 12- to 13-week old were individually caged and placed in a room with a temperature of 10±2°C or 23±2°C for 4 hr before the sampling. We chose mild cold condition because of the cold intolerant phenotype of UCP1-KO mice \(^{(15)}\). The duration of cold exposure treatment was determined in the reference to the previous report where the effect of β3-AR agonist on cir-miR-122 was examined \(^{(9)}\). The mice were anesthetized by intraperitoneal injection of ketamine (75 mg/
kg; Ketalar, Daiichi-Sankyo, Tokyo, Japan) and medetomidine (1 mg/kg; Domitor, Zenoaq, Fukushima, Japan) before blood sampling from the jugular vein. Ethylenediaminetetraacetic acid (EDTA) was used as an anticoagulant for the blood samples. Euthanasia via cervical dislocation was conducted and organs including the liver, interscapular BAT (iBAT), gastrocnemius muscle were quickly taken and transferred into RNAlater storage solution (Life Technologies, Carlsbad, CA, U.S.A) for miRNA analysis.

Blood samples were centrifuged at 2000 rpm for 30 min to harvest the plasma. Samples that were still cloudy after 30 min of centrifuge were centrifuged at 3000 rpm for an additional 30 min before storage. Samples were stored at -80°C until use.

Extraction of miRNA and total RNA

Extraction of miRNA from plasma and tissue was achieved using miRNeasy kit (QIAGEN, Hilden Germany). For plasma samples, 100 μL of QIAzol reagent (QIAGEN) was added to 20 μL of isolated plasma and incubated for 5 min at room temperature. After the addition of 10 μL of 1 nM Cel-miR-39-3p spike-in (QIAGEN) and 20 μL of chloroform, samples were centrifuged at 12,000 x g for 15 min at 4 °C. For tissue samples, 10-20 mg of tissues stored in RNAlater were placed in a tube and 1 mL of QIAzol reagent was added. The samples were then homogenized using Mixer Mill 300 (Retsch, Haan, Germany), for 1 min and centrifuged after at 12,000 x g for 15 min at 4 °C. The upper aqueous phase of each sample, both plasma and tissue, was carefully transferred to a fresh tube, and 1.5 volumes of ethanol was added. Each sample was then applied directly to columns and after washing, miRNA was eluted in 12 and 40 μl of nuclease-free water for plasma and tissue samples, respectively. The quantity of miRNA was measured with Qubit microRNA assay kit (Thermo Fisher Scientific, Eugene, OR, U.S.A) reagents using a Qubit 3.0 Fluorometer (Thermo Fisher Scientific). Extraction of total RNA from tissue was achieved using TRIzol (Thermo Fisher Scientific) according to the manufacturer's instructions.

Real-time PCR

The extracted miRNA was reverse transcribed using a miR-X miRNA First Strand Synthesis kit (Clontech, Palo Alto, CA, U.S.A). Briefly, 1.5 μl of miRNA, with concentrations ranging from 0.4 to 0.6 ng/μL, was mixed with an mRQ enzyme and incubated at 37 °C for 1 h and then at 85 °C for 5 min. After the addition of 100 μl of ultrapure water, 2 μl of the sample was used for real-time PCR. For mRNA analysis, total RNA (2 μg) was reverse-transcribed using a 15-mer oligo(dT) adaptor primer and M-MLV reverse transcriptase (Promega, Madison, WI, U.S.A).

Real-time PCR was performed on a fluorescence thermal cycler (Light Cycler system, Roche Diagnostics, Mannheim, Germany) with FastStart Essential DNA Green Master (Roche Diagnostics), and primers specific to each miRNA or mRNA. For miRNA analysis, mRQ3' primer supplied by miRX miRNA First Strand Synthesis kit (Clontech) and miRNA-specific primer prepared according to the kit manual were used. Other primers used in the study are listed in Table 1.

Expressions of miRNA were normalized to Cel-miR-39-3p or small nuclear RNA U6 (snRU6) as reference. Expressions of mRNA were normalized to the expression levels of Actb.

Plasma non-esterified fatty acid (NEFA) and exosomal CD63 measurement

Plasma NEFA concentration was assayed using a NEFA C kit (Wako, Osaka, Japan) following the manufacturer's instructions.

Exosome level was measured using PS Capture Exosome ELISA Kit Anti Mouse IgG POD (Wako) according to the manufacturer's instructions with a slight modification. Briefly, plasma samples were incubated with stirring at room temperature for 2 hr in the Exosome Capture 96 Well Plate. After washing, anti-mouse CD63 monoclonal antibody (Biolegend,
Table 1. Primer sequences for quantitative real-time PCR.

<table>
<thead>
<tr>
<th>Gene name (gene symbol)</th>
<th>NCBI Reference Sequence number, Product size</th>
<th>Forward, and reverse primer sequence</th>
</tr>
</thead>
<tbody>
<tr>
<td>Small nuclear U6 (snRU6)</td>
<td>XR_003953346.1, 107 bp</td>
<td>5’ – CTCGCTTCGGCAGCACCA – 3’, 5’ – AACGCTTCAGGATTTGCGT – 3’</td>
</tr>
<tr>
<td>Actin beta (Actb)</td>
<td>NM_007393.5, 234 bp</td>
<td>5’ – TCG TTA CCA CAG GCA TTG TCG T – 3’, 5’ – TGC TCG AGT AGA GCA AC – 3’</td>
</tr>
<tr>
<td>Uncoupling protein 1 (Ucp1)</td>
<td>NM_009463.3, 197 bp</td>
<td>5’ – GTG AAG GTC AGA ATG CAA GC – 3’, 5’ – AGG GCC CCC TTC ATG AGG TC – 3’</td>
</tr>
<tr>
<td>Iodothyronine deiodinase 2 (Dio2)</td>
<td>NM_010050.4, 130bp</td>
<td>5’ – CAG TGT GGT GCA GCT CTC CAA TC – 3’, 5’ – TGA ACC AAA GTC CAC CAG – 3’</td>
</tr>
<tr>
<td>Fibroblast growth factor 21 (Fgf21)</td>
<td>NM_020013.4, 154bp</td>
<td>5’ – CTG CGG GTC TAC CAA G – 3’, 5’ – CTG CGC CTA CCA CTG TTC C – 3’</td>
</tr>
<tr>
<td>PR domain containing 16 (Prdm16)</td>
<td>NM_006539175.4, 180bp</td>
<td>5’ – GAC ATT CCA ATC CCA CCA GA – 3’, 5’ – CAC CTC TGT ATC CAG CA – 3’</td>
</tr>
<tr>
<td>Cell death-inducing DNA fragmentation factor alpha (Cidea)</td>
<td>NM_007702.2, 222bp</td>
<td>5’ – CTT ATC AGG GCT GAC TCT GAT G – 3’, 5’ – GGA GGT GAC TCC GCT GTC TAT TC – 3’</td>
</tr>
<tr>
<td>Cytochrome c oxidase subunit 4 (Cox4)</td>
<td>NM_009941.3, 252 bp</td>
<td>5’ – TGA GGC TGA TTG GCA AGA GA – 3’, 5’ – CGA AGC TCT CGT TAA ACT GG – 3’</td>
</tr>
<tr>
<td>Epithelial V-like antigen 1 (Eva1)</td>
<td>NM_007962.4, 111bp</td>
<td>5’ – CCA CTT CTC CTC AGT TTA CAG C – 3’, 5’ – GCA TTT TAA CCG AAC ATC TGT CC – 3’</td>
</tr>
</tbody>
</table>

Data analysis

Statistical analyses were performed using the SPSS Statistics Version 23 software package from IBM (Chicago, IL, U.S.A). Differences between the treatment groups were analyzed by Student’s t-test. P-values < 0.05 were considered to be statistically significant.

Results

First, we exposed mice to a cold temperature of 10°C for 4 hr and examined the gene expression in BAT. Cold exposure significantly increased the expression of the BAT marker, Ucp1, by 2-fold (Fig.1), indicating the activation of BAT. As reported previously, the expressions of Dio2 and Fgf21 were also significantly increased by cold exposure. The change in the expressions of other genes related to BAT thermogenic function including Prdm16, Cidea, and Eva1 was negligible in this condition.

Next, we examined the effect of cold exposure on cir-miR-122. Cir-miR-122 levels of cold exposed mice increased by 3-fold compared to the control mice kept at 23°C (Fig 2A). However, cold exposure did not alter the plasma NEFA concentration (Fig 2B) and exosome level (Fig 2C). These results indicate that cold exposure increased cir-miR-122 was not due to plasma fatty acid level changes.

To identify the source of cir-miR-122 in cold-exposed mice, hepatic content of miR-122 was measured. Cold exposure did not show any changes in both hepatic miR-122 (Fig 3A) and
pre-miR-122 levels (Fig 3B), suggesting that the increase in cir-miR-122 induced by cold exposure was unlikely due to the production nor the secretion from the liver. To examine the involvement of other tissues, iBAT and skeletal muscle were analyzed. The miR-122 level was not affected in iBAT (Fig 3C), but significantly decreased in muscle (Fig 3D).

UCP1-KO mice were used to directly examine the relation between the cold-induced BAT thermogenesis and the change in cir-miR-122 levels. Cold exposure for 4 hr in UCP1-KO mice caused significant increase in the expression of Dio2 and Cidea, and not in Fgf21, Prdm16, and Eva1, although there was a tendency of increase (Fig.4A). These results indicate the cold exposure was sufficient in inducing the SNS-NE-ß-AR pathway for BAT thermogenesis in UCP1-KO mice 10). In contrast to the response of WT mice, cold exposure did not change cir-miR-122 level, as well as plasma NEFA concentration and exosome level, in UCP1-KO mice (Fig 4B-D). Hepatic miR-122 level also failed to show any change in cold-exposed UCP1-KO mice (Fig 4E). MiR-122 level in BAT and skeletal muscle also did not change after cold exposure in UCP1-KO mice (Fig 4 F-G).

Discussion

In this study, we examined the effect of cold exposure on the cir-miR-122 levels in mice. Previously, it was reported that the injection of ß3-AR agonist CL316,243 increased expression and secretion of hepatic miR-122 and therefore cir-miR-122, through its action on WAT to mobilize FAs in circulation 9). In addition to WAT lipolysis, ß3-AR agonist also induces BAT thermogenesis, however, the role of BAT in miR-122 metabolism has not been examined. Cold exposure is a potent physiological stimuli to induce BAT thermogenesis: it activates SNS, which leads to the stimulation of ß3-AR in BAT and WAT, as well as other types of adrenoceptor in many tissues. We found that cold exposure at 10°C for 4 hr resulted in a modest increase in cir-miR-122, without alteration of the plasma NEFA concentration. Thus, the increases in cir-miR-122 after cold exposure is likely independent of the effect of FAs on liver. In agreement with this idea, hepatic miR-122 level showed no change upon cold exposure. Although liver is known as a major source of cir-miR-122, it is plausible that the cold-induced elevation of cir-miR-122 may be not through the secretion from liver.

Since the cold exposure induces shivering and
Cold exposure and circulating miR-122

non-shivering thermogenesis\(^2,3,8\), we examined the involvement of their responsible tissues, BAT and skeletal muscle, as a source of miR-122 upon cold exposure. miR-122 levels in BAT did not show any significant change after the cold exposure, whereas those in muscle were significantly decreased in the cold-exposed mice compared to the control mice. These results suggest that the release of miR-122 from muscle may contribute to the increase in cir-miR-122. It has been reported that skeletal muscle release various kinds of exosomal miRNAs that function in a paracrine or endocrine manner. For example, exosomal miRNAs derived from myotube were reported to downregulate Sirtuin1 (Sirt1) expression in myoblasts and affect their differentiation\(^18\).

In addition, muscle-derived microRNAs that affect skeletal muscle development\(^20\) or those increased after acute exercise\(^19\) were reported. Thus, it is possible that muscle secretes miRNAs upon cold exposure. Since we found that miR-122 level in muscle is very low compared to that in liver (\(>200\)-fold lower in muscle than that in liver), the physiological significance of this pathway is unknown. However, since skeletal muscle is the largest organ as total mass in whole body than other organs, it may give a significant contribution to circulating level of miR-122. Otherwise, it is also likely that muscle releases miR-122 to the circulation to reduce its intracellular level. In liver, the inhibition of miR-122 is reported to enhance fatty acid oxidation\(^16\), possibly through the increase in the expression of target gene Sirt1 and subsequent activation of AMP-activated protein kinase pathway\(^25\).

Thus, the reduced intracellular level of miR-122 in muscle may result in the increase in fatty acid oxidation, contributing to the effective supply of energy source for shivering thermogenesis.

In contrast to the results in WT mice, cold exposure in UCP1-KO mice did not cause the increase in the cir-miR-122 nor decrease in miR-122 in muscle, indicating that activation of UCP1 thermogenesis in BAT is essential for the release of miR-122 from muscle. It is not clear how the

Fig. 3. Content of miR-122 and pre-miR-122 in tissues of wild-type mice after cold exposure.

Mice were exposed to 23°C (Control) or 10°C (Cold) for 4 hr. Tissue samples were taken and miR-122 levels in liver (A), gastrocnemius muscle (C) and BAT (D) (n=11 for control and n=8 for cold group) and pre-miR-122 in liver (B) (n=4 for control and cold groups) were measured by real-time PCR. Data were normalized to the levels of small nuclear RNA U6. Values are expressed as means ± SE. *P < 0.05, Student’s t-test.

Fig. 4. Effect of cold exposure on gene expressions, plasma parameters, and tissue miR-122 levels in UCP1-KO mice.

UCP1-KO mice were exposed to 23°C (Control) or 10°C (Cold) for 4 hr. Expressions of thermogenic genes in BAT were measured by real-time PCR (A). Plasma miR-122 levels (B), NEFA concentrations (C) (n=6 for control and n=4 for cold group), and CD63 levels (D) (n=4 for control and cold groups) were measured. The miR-122 levels in liver (E), BAT (F), and gastrocnemius muscle (G) were also measured (n=6 for control and n=4 for cold group). Values are expressed as means ± SE. *P < 0.05, Student’s t-test.
status of UCP1 activity in BAT was transmitted to muscle. Recently, it was reported that cold stimulation induces the release of succinate from muscle, and it is subsequently taken up by BAT, activating UCP1 thermogenesis\(^\text{27}\). Although it is unknown if the release of succinate is dependent on BAT activity, it is plausible that there is some inter-organ communication between BAT and muscle. It is also possible that the miR-122 release from muscle did not occur in UCP1-KO mice because of a compensatory phenotypic change for the loss of UCP1. It has been reported that non-shivering thermogenesis in muscle depending on SERCA or sarcolipin compensates the loss of UCP1-dependent thermogenesis in the BAT of UCP1-KO mice\(^\text{2,3,29,30}\). Such compensatory changes of muscle may possibly associate with the lack of the miR-122 release from muscle in UCP1-KO mice.

In summary, we found that cir-miR-122 is increased after cold exposure possibly through the secretion from muscle (Fig. 5). In addition, we found that the cold-induced increase in cir-miR-122 was dependent on UCP1-thermogenesis in BAT. It is not clear how BAT thermogenesis induced miR-122 secretion from muscle, however, there may be some cross talk between BAT and muscle as that reported between BAT and liver\(^\text{1,11,33}\). Further study is required to reveal the precise mechanism for the cold-induced increase in the cir-miR-122.

**Acknowledgements**

This study was supported by JSPS KAKENHI Grant Numbers 16K15485, 17K08118, 18H02274, and 18J21697.

**References**


Cold exposure and circulating miR-122


30) Shabalina IG, Hoeks J, Kramarova TV, Schrauwen P, Cannon B, Nedergaard J. Cold tolerance of UCP1-ablated mice: A skeletal muscle mitochondria switch toward lipid oxidation with marked UCP3 up-regulation not associated with increased basal, fatty acid- or ROS-induced uncoupling or enhanced GDP effects. Biochim Biophys Acta, Bioenerg 1797, 968–980, 2010.


SHORT COMMUNICATION

Regional Study

Isolation of methicillin-resistant *Staphylococcus aureus* ST398 from pigs in Japan

Yoshimasa Sasaki1,2,3, *, Tetsuo Asai2, Mika Haruna3, Tsuyoshi Sekizuka4, Makoto Kuroda4 and Yukiko Yamada3

Abstract
Methicillin-resistant *Staphylococcus aureus* (MRSA) is a major concern for public health. Recent decades have seen the emergence and worldwide spread of livestock-associated MRSA, particularly sequence type (ST) 398, in pigs. Two investigations were conducted to confirm the presence of MRSA ST398 in domestic Japanese pigs. In the first investigation, nasal swabs were collected from 500 pigs on 50 pig farms between August 2012 and February 2013. MRSA ST398 was isolated from four pigs from a farm. In the second investigation, nasal swabs were collected from 480 pigs on 24 pig farms between November 2013 and March 2014. MRSA ST398 was isolated from 54 pigs on five farms. These results indicate that MRSA ST398 has become established in domestic Japanese pigs.

Key Words: MRSA, ST398, pig

Transmission of methicillin-resistant *Staphylococcus aureus* (MRSA) between pigs and humans in European countries was first reported in 20052,26. In a Dutch hospital located in a pig-dense area, a three-fold increase in MRSA incidence was observed over a few years25. These reports suggested that pig farming was a risk factor for MRSA carriage in the families of farmers and of their neighbours. Since then numerous studies of MRSA in pigs have been conducted in many countries, showing that some sequence type (ST) clonal lineages of MRSA, such as ST5, ST9, ST97, and ST398 are present in pigs1,8,16,20,22. These lineages can cause human MRSA infections2,6,12,15,18, are called livestock-associated MRSA (LA-MRSA) and are of great concern in human and veterinary medicine. Most LA-MRSA isolates from pigs belong to ST3988,16,22.

Despite the prevalence of this MRSA ST in other regions, there had been no evidence of it in pigs in Japan. In Japan, approximately one thousand pigs are imported annually19, all of which are required to undergo quarantine
inspections prior to import. However, carriage of MRSA is not inspected because it is not a targeted infectious disease according to the Domestic Animal Infectious Disease Control Law. If pigs infected with MRSA are imported, MRSA could be introduced and spread among domestic pig farms. Evidence of this can be seen in Republic of Korea, which imports breeding pigs from Canada, Denmark and the USA, where MRSA ST398 was isolated from pigs in 2008\(^{16}\). According to e-Stat, which is a portal site for the Japanese Government Statistics (https://www.e-stat.go.jp), Japan has imported live pigs from these three countries for breeding purposes. To determine whether MRSA ST398 was present in domestic Japanese pig farms, we conducted two surveys of a large number of pig farms in geographically disparate regions in Japan.

In the first investigation, veterinarians visited a total of 50 pig farms (48 farrow-to-finish and 2 finishing farms) in four regions (ten in Tohoku, 23 in Kanto, seven in Tokai region on Honshu; and ten in Kyushu) between August 2012 and February 2013. These four regions are the main pork producing regions in Japan: accommodating more than 80% of the pigs in the whole country\(^{19}\). All farms participated voluntarily on condition of anonymity. On each farm, ten animals (6–29 weeks of age) were selected by veterinarians, totalling 500 pigs. A nasal swab sample was collected from each animal using a BBL CultureSwab Plus Amies Gel with Charcoal, Single Swab (Becton Dickinson, MD, USA). Samples were delivered under refrigeration to the Research Institute for Animal Science in Biochemistry and Toxicology (Kanagawa, Japan) within 24 hr. MRSA isolation was conducted within 48 hr of sampling according to the protocol recommended by the baseline survey on the prevalence of MRSA in holdings with breeding pigs in the EU\(^{20}\). In brief, the tip of each nasal swab was added to a tube containing 9 ml of Mueller Hinton broth (Becton Dickinson) containing 3.5 mg/l cefoxitin (Sigma-Aldrich, Tokyo, Japan) and 75 mg/l aztreonam (MP Biomedicals, OH, USA), and incubated for 24 hr at 37 °C. The resulting cultures were grown in CHROMagar MRSA medium (CHROMagar, Paris, France) for 24 hr at 37 °C. When suspected MRSA colonies were observed, up to three colonies per sample were isolated and identified using the API Staph system (Sysmex bioMérieux, Tokyo, Japan). One MRSA isolate per sample was subjected to molecular typing and antimicrobial susceptibility testing. Staphylococcal cassette chromosome mec (SCCmec) typing was performed using multiplex PCR-based amplification as previously described\(^{13}\). MRSA isolates were also characterized by spa repeat determination\(^{11}\) and multilocus sequence typing\(^{9}\). Presence of genes encoding Panton-Valentine leukocidin toxin (pvl) was determined through PCR amplification\(^{17}\). S. aureus ATCC BAA-1556 was used as a pvl-positive control. Minimal inhibitory concentrations (MICs) of ten antimicrobials (ampicillin, chloramphenicol, ciprofloxacin, clindamycin, erythromycin, gentamicin, teicoplanin, tetracycline, oxacillin, and vancomycin) were determined using the broth microdilution method in dried plates (Eiken Chemical) following the guidelines of the Clinical and Laboratory Standards Institute\(^{4, 5}\). S. aureus ATCC 29213 was used for quality control.

MRSA was isolated from five (1%) pigs aged 5 months on two (4%) of the farms surveyed (farms a and d) (Table), both located in the Kanto region. All five MRSA isolates had the class A mec gene complex but were negative for ccr, and were classified as atypical. The pvl gene was not detected in any of these isolates. One MRSA isolate from “Farm a” was classified as spa types t002 and ST5 and was found to be resistant to six antimicrobials. The remaining four isolates were obtained from four different pigs reared in the same pen in “Farm d.” All isolates were classified as ST398 and a novel spa type, t16450 (08-16-02-111-02-25-34-24-25). All four ST398 isolates were resistant to six or more antimicrobials.
In the second investigation, veterinarians visited 24 pig farms (21 farrow-to-finish and 3 finishing farms) in the Kanto region between November 2013 and March 2014. Of the 24 pig farms, 21 had also participated in the first investigation. Nasal swabs were collected from 20 pigs (6–28 weeks of age) from at least two age groups at each farm, with each age group coming from one pen. The pigs tested in both investigations were determined to be healthy based on visual inspections by veterinarians.

MRSA was isolated from 78 pigs on eight farms, all of which had been surveyed in the initial investigation. Of these eight farms, two (farms a and d) were positive for MRSA in the first investigation. MRSA isolates belonging to ST5, ST10, and ST97 were isolated from three farms (a, b, and c). ST5, ST10, and ST97 isolates were classified as spa types t002, t002, and t1236, respectively. MRSA belonging to ST398 were isolated from five farms (d, e, f, g, and h) located within a 2 km radius of each other. From a total of 54 MRSA ST398 isolates, 29, 11, and 14 isolates were classified as spa types t16450, t3934, and t034, respectively. ST398/t16450, ST398/t034, and ST398/t3934 were isolated from four (d, e, f, and g), two (f and g) and one (h) farms, respectively. All 78 MRSA isolates were negative for pvl. SCCmec types of ST5/t002, ST10/t002, ST97/t1236, and ST398/t034 were IVb, IVa, V, and V, respectively. SCCmec types of ST398/t16450 and ST398/t3934 were classified as atypical, as no amplicons resulted from PCR for ccr typing.

Studies on the presence of MRSA in domestic Japanese pigs were conducted at abattoirs in 2009 and 2013 showed the presence of MRSA ST5, ST97 and ST221, but not MRSA ST398 or ST10. To the best of our knowledge, the isolation of MRSA ST398 from four pigs on a pig farm in the Kanto region in November 2012, is the first isolation of MRSA ST398 in pigs in Japan. Fourteen months later, in January 2014, MRSA ST398 was isolated from pigs on five farms, including the MRSA-positive farm from the first investigation. The number of sampled pigs at each farm in the second survey was twice that of the first. Although the probability of MRSA detection may have increased due to the larger sample size, these findings indicate that MRSA ST398 may have become established in Japan.

### Table. Isolation of MRSA from pigs

<table>
<thead>
<tr>
<th>Farm code</th>
<th>Date of sampling</th>
<th>Prevalence of MRSA</th>
<th>No. of isolates</th>
<th>characteristics of MRSA isolates</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>ST/spa type/mec type/SCCmec type/antimicrobial resistance profile</td>
</tr>
<tr>
<td>First investigation</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>a</td>
<td>20 Nov. 2012</td>
<td>1/10</td>
<td>1</td>
<td>ST5/t002/A/atypical/ABPC, CLDM, CP, EM, MPIPC, TC</td>
</tr>
<tr>
<td>d</td>
<td>15 Nov. 2012</td>
<td>4/10</td>
<td>2</td>
<td>ST398/t16450/A/atypical/ABPC, CLDM, CP, EM, MPIPC, TC, GM</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>ST398/t16450/A/atypical/ABPC, CLDM, CP, EM, MPIPC, TC</td>
</tr>
<tr>
<td>Second investigation</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>d</td>
<td>15 Nov. 2012</td>
<td>4/10</td>
<td>2</td>
<td>ST5/t002/B/IVb/ABPC, CLDM, CP, EM, MPIPC, TC</td>
</tr>
<tr>
<td>b</td>
<td>17 Dec. 2013</td>
<td>12/20</td>
<td>1</td>
<td>ST10/t002/B/IVa/ABPC, CLDM, CP, EM, MPIPC, TC</td>
</tr>
<tr>
<td>c</td>
<td>4 Feb. 2014</td>
<td>8/20</td>
<td>8</td>
<td>ST97/t1236/C/V/ABPC, CLDM, CP, EM, MPIPC, TC</td>
</tr>
<tr>
<td>d</td>
<td>9 Jan. 2014</td>
<td>18/20</td>
<td>18</td>
<td>ST398/t16450/A/atypical/ABPC, CLDM, CP, EM, MPIPC, TC, GM</td>
</tr>
<tr>
<td>e</td>
<td>9 Jan. 2014</td>
<td>2/20</td>
<td>2</td>
<td>ST398/t16450/A/atypical/ABPC, CLDM, CP, EM, MPIPC, TC</td>
</tr>
<tr>
<td>f</td>
<td>9 Jan. 2014</td>
<td>9/20</td>
<td>6</td>
<td>ST398/t16450/A/atypical/ABPC, CLDM, CP, EM, MPIPC, TC</td>
</tr>
<tr>
<td>g</td>
<td>9 Jan. 2014</td>
<td>11/20</td>
<td>11</td>
<td>ST398/t16450/A/atypical/ABPC, CLDM, CP, EM, MPIPC, TC</td>
</tr>
<tr>
<td>h</td>
<td>12 Mar. 2014</td>
<td>14/20</td>
<td>14</td>
<td>ST398/t16450/A/atypical/ABPC, CLDM, CP, EM, MPIPC, TC</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>ST398/t16450/A/atypical/ABPC, CLDM, CP, EM, MPIPC, TC</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>ST398/t16450/A/atypical/ABPC, CLDM, CP, EM, MPIPC, TC</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>ST398/t16450/A/atypical/ABPC, CLDM, CP, EM, MPIPC, TC</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>ST398/t16450/A/atypical/ABPC, CLDM, CP, EM, MPIPC, TC</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>ST398/t16450/A/atypical/ABPC, CLDM, CP, EM, MPIPC, TC</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>ST398/t16450/A/atypical/ABPC, CLDM, CP, EM, MPIPC, TC</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>ST398/t16450/A/atypical/ABPC, CLDM, CP, EM, MPIPC, TC</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>ST398/t16450/A/atypical/ABPC, CLDM, CP, EM, MPIPC, TC</td>
</tr>
</tbody>
</table>

lineages, t034, t3934 and t16450, were found in the present study. ST398/t034 is one of the major lineages of LA-MRSA in pigs\textsuperscript{1,8,16,22} and most of which have SCC\textit{mec} type V and are negative for \textit{pvl}\textsuperscript{16,22}. ST398/t3934 is one of the minor lineages in pigs\textsuperscript{7}. ST398/t16450 was first isolated in the world. The isolation of MRSA ST10 in pigs has never been reported in the world. High prevalence (60%, 12/20) in pigs in Farm b suggests that ST10 is also adapted to pigs as well as ST5, ST97 and ST398 lineages.

Koyama et al.\textsuperscript{14} described the isolation of \textit{pvl}-positive MRSA ST398 from a Chinese woman receiving steroid therapy for systemic lupus erythematosus in a Japanese hospital in 2015, representing the first documented case of MRSA ST398 in a human in Japan, while until 4 days prior to admission to the hospital, the subject had been outside of Japan for approximately 2 months. The patient had had no contact with animals or persons working or living with animals, and the MRSA ST398 isolate obtained was genetically close to a community-associated MRSA lineage detected in China. Thus, the subject was unlikely to have been infected with this isolate from animals in Japan. Nakaminami et al.\textsuperscript{21} recently reported a case of intractable arthritis of the shoulder joint caused by \textit{pvl}-positive MRSA ST1232 (a single-locus variant of ST398 belonging to clonal complex 398) in a patient in 2018. The transmission route was unclear because the patient reported no overseas travel or animal contact.

Furuno et al.\textsuperscript{10} recently reported that at least 12 of 125 pigs imported from Europe and North America tested positive for MRSA ST398 during the quarantine period. These pigs infected with MRSA ST398 must have been released to domestic pig farms because the import of infected pigs is not prohibited, suggesting that the MRSA ST398 lineages isolated in this study may have been introduced into Japan by imported pigs. In this study, MRSA ST398 was not isolated from any regions other than Kanto. However, 6 years have passed since the first isolation of MRSA ST398. Because repeated importation of pigs infected with MRSA increases the possibility of MRSA spread throughout Japan, it is necessary to monitor the prevalence of MRSA ST398 in pigs throughout Japan.

Acknowledgements

This work was supported by the Ministry of Agriculture, Forestry and Fisheries of Japan. The authors wish to thank the pig farms and veterinarians for providing samples for this study.

Conflict of interest

None to declare.

References


19) Ministry of Agriculture, Forestry and Fisheries in Japan. The 89th statistical yearbook of Ministry of Agriculture, Forestry
and Fisheries in Japan, 2015.


Clinical evaluation of pentosan polysulfate as a chondroprotective substance in native Mongolian horses

Mijiddorj Tsogbadrakh1), Takafumi Sunaga1), *, Eugene Bwalya1), Suranji Wijekoon1), Ekkapol Akaraphutiporn1), Yanlin Wang1), Carol Mwale1), Adiya Naranbaatar2), Sangho Kim1), Kenji Hosoya1), Damdinsuren Alimaa2) and Masahiro Okumura1)

Abstract
Pentosan polysulfate (PPS) is widely used as therapeutic intervention for joint diseases in humans and animals, while objective confirmation has not been established yet. The purpose of this study was to provide the objective measure of the efficacy of PPS. Twenty-five healthy Mongolian horses were randomly assigned in three groups. Three different doses of PPS, 0/1.2/3.0 mg/kg, were injected intramuscularly one a week for consecutive 4 weeks. On 14 and 28 days after the initial administration, relative ratios of serum COMP/CPII were 97.9/87.6/61.8 and 94.2/104.3/88.1 in 0/1.2/3.0 mg/kg PPS, respectively. The results revealed that balance of cartilage metabolism could be significantly brought to an anabolism dominant state by PPS injections in dose dependent manor in field fed horses in Mongolia.

Key Words: pentosan polysulfate, chondroprotection, horse

Pentosan polysulfate (PPS) is a semi-synthetic polysulfated xylan derived from beechwood8). PPS is weak heparinoid indicating slight anticoagulant activities9) and anti-inflammatory properties, which are widely used for symptomatic managements for selective diseases, including interstitial cystitis16), osteoarthritis1) and mucopolysaccharidosis6) in human beings and veterinary patients. The pathobiology pathways, to which PPS could interfere as therapeutic interventions in osteoarthritis, were speculated to include induction and maintenance of synovitis, microcirculation in subchondral bones and surrounding structures resulting to bone sclerosis, and degradation of articular cartilage5). Despite popularities of use of PPS for equine patients have been increased18), clinical factual observations are surely very limited to prove the evidence for PPS to restrain any of the above-mentioned pathways. The objective of the present study was to provide reliable clinical confirmation that PPS could control those pathways, particularly degradative activity of articular cartilage metabolism in horses with ordinally field-feeding.
In the present study, a total of 25 native Mongolian horses (average body weight ± standard error: 242±9 kg; 14 males and 11 females), which were two years of age and all after breaking, were randomly selected at a feeder in one plain in Khentii province, Mongolia, in September, 2017. All the horses had free access to grass and water daily in the same pasture condition. Before being assigned to this study, horses were examined to prove its general physical condition, serum biochemistry profiles including hepatic and renal functional measures and orthopedic fitness being normal and healthy. Four doses of PPS (OJI-200EI, Oji Holdings Co., Tokyo, Japan) at 3.0 mg/kg or 1.2 mg/kg were injected intramuscularly one a week in 20 horses, as of PPS dosage, injected each group of horses was consisted with 10 horses. In the rest five horses, phosphate-buffered saline solutions were injected in the same course of PPS administrations in other 20 horses. Horses were randomly assigned in each treatment group and entire procedures of the administration of PPS in an open label fashion. Use of PPS to these horses assigned in this study was on the basis of the owners’ preference of its clinical use for prevention of osteoarthritis and maintained skeletal health. Evaluation of horses in general physical and orthopedic conditions was done every week when PPS was injected. Blood specimens were collected every 2 weeks, and serum biochemistry profiles, including total alanine aminotransferase (ALT), lactate dehydrogenase (LDH), blood urea nitrogen (BUN) and creatinine (Cr), were measured (Fuji DryChem NX500, Fujifilm, Tokyo, Japan) after sera being separated and prepared. Parameters of serum biochemistry examined were all in the normal reference ranges. Values were described as mean±standard deviation.

### Table 1. Blood biochemistry examination on ALT, LDH, BUN and Cr

<table>
<thead>
<tr>
<th>days after injection</th>
<th>PPS 3.0 mg/kg bw</th>
<th>PPS 1.2 mg/kg bw</th>
<th>PPS 0 mg/kg bw</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ALT(U/I)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0</td>
<td>16.6±6.5</td>
<td>18.4±14.9</td>
<td>11.8±2.8</td>
</tr>
<tr>
<td>14</td>
<td>9.8±2.2</td>
<td>10.3±2.5</td>
<td>8.2±2.2</td>
</tr>
<tr>
<td>28</td>
<td>10.6±2.2</td>
<td>9.2±6.1</td>
<td>7.2±1.2</td>
</tr>
<tr>
<td><strong>LDH(U/I)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0</td>
<td>481±105</td>
<td>634±165</td>
<td>465±119</td>
</tr>
<tr>
<td>14</td>
<td>620±112</td>
<td>452±157</td>
<td>363±173</td>
</tr>
<tr>
<td>28</td>
<td>535±73</td>
<td>542±144</td>
<td>351±103</td>
</tr>
<tr>
<td><strong>BUN(mg/dl)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0</td>
<td>19.1±2.6</td>
<td>20.9±4.6</td>
<td>19.0±5.2</td>
</tr>
<tr>
<td>14</td>
<td>20.9±3.3</td>
<td>19.8±4.8</td>
<td>17.1±4.1</td>
</tr>
<tr>
<td>28</td>
<td>19.2±1.8</td>
<td>17.3±4.3</td>
<td>11.3±3.4</td>
</tr>
<tr>
<td><strong>Cr(mg/dl)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0</td>
<td>0.52±0.24</td>
<td>0.65±0.10</td>
<td>0.54±0.12</td>
</tr>
<tr>
<td>14</td>
<td>0.88±0.08</td>
<td>0.84±0.15</td>
<td>0.60±0.13</td>
</tr>
<tr>
<td>28</td>
<td>0.84±0.05</td>
<td>0.93±0.16</td>
<td>0.58±0.14</td>
</tr>
</tbody>
</table>

Blood specimens were collected every 2 weeks, and serum biochemistry profiles, including total alanine aminotransferase (ALT), lactate dehydrogenase (LDH), blood urea nitrogen (BUN) and creatinine (Cr), were measured (Fuji DryChem NX500, Fujifilm, Tokyo, Japan) after sera being separated and prepared. Parameters of serum biochemistry examined were all in the normal reference ranges. Values were described as mean±standard deviation.
days after the initial administration. Significance of PPS administration on values of the markers in the course was on the basis of dose-dependent manner, which was evaluated by the linear mixed effects models fit by residual maximum likelihood estimation. $P$ value estimating statistical significance was set less than 0.05.

All horses showed no unbeneficial presentations in relation to series of PPS administration during the observation period. No symptomatic pathologies in joints, its adjacent structures and injection sites in the neck were found, and parameters of serum biochemistry examined were all in the normal reference ranges (Table 1). After 14 and 28 days from the initial administration, the relative ratios of serum relative values of two markers, COMP to CPII, representing balance of articular cartilage metabolism were 97.9/87.6/61.8 and 94.2/104.3/88.1 in three different dosages of PPS including 0, 1.2 and 3.0 mg/kg, respectively (Fig. 1). The ratios in 3.0 mg/kg PPS showed some tendency to be lower than those of 0 mg/kg PPS on both 14 and 28 days after the initial injection ($P=0.2517$; $P=0.1762$, respectively) (Fig. 1). The reduction of the ratio of COMP/CPII in different doses of PPS was simulated on the linear mixed effects models (Fig. 2). On the analysis, sequential injections of PPS showed the tendency to be positively correlated to values of CPII, an anabolic marker of cartilage metabolism ($P=0.167$). PPS dose and sequential injections showed negative correlation to values of COMP with certain significance ($P=0.027$).

This investigation suggested a clinical evidence to prove one of pathobiology pathways, degradative activities of cartilage, where PPS would effectively suppress in the course of joint diseases. In previous studies, PPS is suggested to have suppressive effects on some of classic mitogen activated protein kinase pathways in cultured chondrocytes, to regulate phenotype of chondrocytes in appropriate condition, to down-regulate induction osteoclastic differentiation of hematopoietic stem cells simulating inflamed synovitis and to show suppressive inflammatory changes of synovium in rodent models in vivo. In horses, while much attention, especially for owners and trainers of racing horses, is being paid to PPS as both the ratio of COMP/CPII at 14 and 28 days after the initial injection of PPS.

The ratios of COMP/CPII in horses with 3.0 mg/kg PPS showed some tendency to be lower than those with 0 mg/kg PPS on both 14 and 28 days after the initial injection ($P=0.2517$; $P=0.1762$, respectively).

Relative values of each cartilage metabolic marker represented %values in comparison with ones at the initial administration. Analysis of variance (ANOVA) was used to compare ratios of relative values of COMP/CPII among different dose groups of PPS on 14 or 28 days after the initial injections. Significant difference was defined as $P<0.05$. Significance of PPS administration on values of the markers in the course was evaluated by the linear mixed effects models fit by REML. Significant difference was defined as $P<0.05$.
preventive and therapeutic use to joint fitness, some studies suggest some positive opinions but none of them reached to provide clinical evidence using objective measures\textsuperscript{3,7}. This would suggest that values of cartilage metabolic markers from large animals would have much variation, which could compromise to comprehend the obtained data properly. Statistical analysis using means or medians were not suitable to absorb the physiological variation of results.

The results on the balance of anabolic (CPII) and catabolic (COMP) markers suggested tendency, which PPS would bring it to more less catabolic in comparison with negative control (Fig. 1). The results analyzed by using the linear mixed effects models fit by REML revealed that degradation marker changes were significant to correlate with doses and sequential uses of PPS, proving that PPS would reduce degradative activities of cartilage in the course of joint diseases (Fig. 2). Domestic Mongolian horses are being fed by nomads in a traditional fashion customized for the specific climate and environment in Mongolian steppe, resulted in excess athletic and regular migration activities in summer and less movement and very limited nutritional intake in winter. On its life style, native horses are forced to have much physical stress on the skeletal system through active movement on the rough surface of the ground in warm season\textsuperscript{11,13}. This would surely increase degradative activity of cartilage on joint surfaces causing future osteoarthritis, which would be one of the most prevalent diseases in athletic horses\textsuperscript{19}. In human trial to use PPS for mild knee osteoarthritis, significant reduction of C2C, one of degradation markers of cartilage, was observed, which promised suppressive effects for PPS on degradation of cartilage\textsuperscript{10}. Our observation of two cartilage metabolic markers would be the first evidence of anti-degradative effects of PPS in horses at a clinical setting.

No adverse effects were seen in serum biochemistry profiles and orthopedic examinations. Basically, this semi-synthetic substance is believed to be very safe and orally used for the only medical treatment for human interstitial cystitis for lifelong use to relief pain under the approval and registration by United States Food and drug Administration\textsuperscript{19}. However, recently some ophthalmologists reported the augmentation that long time use of oral PPS for 15 years or more might cause vision threatening pathologies in human beings aged more than 60 years old\textsuperscript{14}. While short time use of PPS would not be expected to lead any serious adverse events, more knowledge and experience related to long time use of PPS in horses are necessary to establish its safety.

In conclusion, through our results from the analysis of cartilage metabolic markers related to PPS injections, reliable clinical confirmation that this substance could reduce degradative activity of articular cartilage metabolism in native Mongolian horses with ordinally field-feeding.

Acknowledgements

The authors sincerely pay appreciation to OJI Holdings corporation and colleagues to provide injectable PPS and tireless technical supports to complete measure biomarkers.

References


The Japanese Journal of Veterinary Research (JJVR) is an official journal published quarterly by the Graduate School of Veterinary Medicine, Hokkaido University. JJVR covers the complete range of topics and investigations in veterinary medicine and veterinary sciences. JJVR will be released to major research organizations chosen by the Graduate School of Veterinary Medicine, Hokkaido University. Readers can also access peer-reviewed articles already published in JJVR at the website (http://eprints.lib.hokudai.ac.jp/bulletin/jjvr) for the Hokkaido University Collection of Scholarly and Academic Papers (HUSCAP) (http://eprints.lib.hokudai.ac.jp/dspace).

Author Information
Guidelines for authors can be found either in the first issue of each volume of the journal or at the website (http://jjvr.vetmed.hokudai.ac.jp/instructions.html). These include the editorial and copyright policies and detailed instructions for manuscript preparation. For more information, please contact the editorial office: jjvr@vetmed.hokudai.ac.jp

JJVR, Faculty of Veterinary Medicine, Hokkaido University
Sapporo 060-0818, Japan

Editorial Committee: http://jjvr.vetmed.hokudai.ac.jp
Editorial Office: Library, Faculty of Veterinary Medicine, Hokkaido University, Sapporo 060-0818, Japan. Phone: +81-11-706-5179. E-mail: jjvr@vetmed.hokudai.ac.jp

Printer: HAKUYO PRINTING Co., Ltd.
Sapporo 060-0033, Japan. Phone: +81-11-241-9341

ISSN: 0047-1917
Among people in close contact
Through respiratory droplets from infected people

• Clean your hands often at least 20s with soap or hand sanitizer (> 60% alcohol)
• Avoid touching eyes, nose and mouth
• Avoid close contact with people
• Keep a safe distance from others (more than 1.8 m)
• Avoid staying in a narrow space with others
• Stay home as much as possible

World Health Organization (WHO)
Center for Disease Control and Prevention (CDC)
Ministry of Health, Labor and Welfare (MHLW)